Warsaw breakage syndrome

Mendelian MONDO:0013252 Pathograph 30 Show in embeddings browser Neurodevelopmental disorder Genetic disease

Warsaw breakage syndrome (WABS), also called DDX11-related cohesinopathy, is an ultra-rare autosomal recessive developmental disorder caused by biallelic pathogenic variants in DDX11. Its core clinical triad is congenital severe microcephaly, prenatal and postnatal growth restriction, and congenital sensorineural hearing impairment associated with cochlear hypoplasia. Sister chromatid cohesion defects are a consistent cellular signature, whereas cross-linker-induced chromosome breakage is variable and may be absent. The mechanistic bridge from replication-coupled cohesion failure to the tissue-selective developmental phenotype remains unresolved; altered rDNA transcription and ribosome biogenesis constitute a supported but still provisional additional disease mechanism.

Ask OpenScientist

Ask a research question about Warsaw breakage syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
8
Pathophys.
18
Phenotypes
2
Hypotheses
4
Gaps
30
Pathograph
1
Genes
6
Medical Actions
4
Differentials
4
Models
5
References
1
Deep Research
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
DDX11-related cohesinopathy follows autosomal recessive inheritance. When both parents carry a familial pathogenic variant, each pregnancy has a 25% probability of an affected child, a 50% probability of an unaffected carrier, and a 25% probability of an unaffected non-carrier. Once the familial variants are known, carrier, prenatal, and preimplantation genetic testing are possible.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:31169992 SUPPORT Human Clinical
"DDX11-related cohesinopathy is inherited in an autosomal recessive manner."
Directly states the mode of inheritance.
PMID:31169992 SUPPORT Human Clinical
"If both parents are known to be heterozygous for a DDX11 pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier."
Provides the recurrence risks used in genetic counseling.
◈

Mechanistic Hypotheses

2
Replication-coupled cohesion and genome-maintenance model
replication_coupled_cohesion_model CANONICAL
Evidence balance 2 support
The best-supported model places DDX11 at nascent DNA with the fork-protection factor Timeless, where it promotes cohesin association during DNA replication. Pathogenic DDX11 dysfunction slows replication forks and impairs sister chromatid cohesion, producing premature chromatid separation and a variable genotoxin-sensitive chromosome-instability phenotype. How these cellular defects produce organ-selective congenital abnormalities is not yet known.
Pathograph links
Pathogenic DDX11 helicase dysfunction -> Slowed replication forks and defective replication-coupled cohesin loading DIRECT Loss of DDX11 DNA binding and fork-localized function slows forks and compromises recruitment or stabilization of cohesin during replication.
Pathogenic DDX11 helicase dysfunction -> Variable cross-link-induced chromosome breakage UNKNOWN DDX11-deficient cells can become hypersensitive to DNA cross-linking stress, although this phenotype is not penetrant across all affected individuals.
Slowed replication forks and defective replication-coupled cohesin loading -> Sister chromatid cohesion defect DIRECT Failure to couple cohesin to DNA replication reduces functional cohesion.
Sister chromatid cohesion defect -> Premature chromatid separation and railroad chromosome morphology DIRECT Insufficient cohesion permits premature separation of chromatids and centromeres, producing the characteristic railroad-track appearance.
Sister chromatid cohesion defect -> Impaired embryonic proliferation and tissue development INDIRECT UNKNOWN INTERMEDIATES A developmental consequence is plausible from animal loss-of-function models, but the relevant human tissues and intervening mechanisms are unknown. Intermediates: Tissue-specific replication stress, altered transcription, cell-cycle delay, or cell loss.
Impaired embryonic proliferation and tissue development -> Intrauterine growth retardation INDIRECT UNKNOWN INTERMEDIATES Prenatal growth failure is universal in reported individuals, but the causal tissue and cellular bottleneck are not established.
Impaired embryonic proliferation and tissue development -> Postnatal growth retardation INDIRECT UNKNOWN INTERMEDIATES Persistent growth deficiency may reflect reduced cell production and nutritional factors; their relative contributions are unknown.
Impaired embryonic proliferation and tissue development -> Congenital microcephaly INDIRECT UNKNOWN INTERMEDIATES Reduced prenatal brain growth is plausibly downstream of impaired development, but neural progenitor-specific causality has not been tested.
Impaired embryonic proliferation and tissue development -> Abnormal brain morphology INDIRECT UNKNOWN INTERMEDIATES Structural brain anomalies occur in a minority of affected individuals, but their lineage-specific developmental mechanism remains unknown.
Impaired embryonic proliferation and tissue development -> Abnormal cortical gyration INDIRECT UNKNOWN INTERMEDIATES Poor sulcation, delayed gyration, and focal lissencephaly implicate cortical development through untested neural-progenitor intermediates.
Impaired embryonic proliferation and tissue development -> Hypoplasia of the corpus callosum INDIRECT UNKNOWN INTERMEDIATES Callosal hypoplasia is plausibly developmental, but no DDX11-dependent axon-guidance or commissural-neuron mechanism has been demonstrated.
Impaired embryonic proliferation and tissue development -> Cerebellar vermis hypoplasia INDIRECT UNKNOWN INTERMEDIATES Vermian hypoplasia is reported clinically, but the affected progenitor population and causal molecular branch are unresolved.
Impaired embryonic proliferation and tissue development -> Congenital sensorineural hearing impairment INDIRECT UNKNOWN INTERMEDIATES Hearing impairment reflects abnormal cochlear development; the relevant embryonic cell population and molecular route from DDX11 remain unknown.
Impaired embryonic proliferation and tissue development -> Cochlear malformation INDIRECT UNKNOWN INTERMEDIATES The tissue-selective basis of cochlear hypoplasia is unresolved.
Impaired embryonic proliferation and tissue development -> Intellectual disability INDIRECT UNKNOWN INTERMEDIATES Cognitive impairment is associated with congenital brain growth and hearing-language effects, but its direct cellular mechanism is unknown.
Impaired embryonic proliferation and tissue development -> Delayed speech and language development INDIRECT KNOWN INTERMEDIATES Severe hearing impairment is a known contributor to speech delay, while intellectual disability may additionally limit receptive language. Intermediates: Congenital sensorineural hearing impairment and limited auditory input.
Impaired embryonic proliferation and tissue development -> Global developmental delay INDIRECT UNKNOWN INTERMEDIATES Mild developmental delay is variably present; affected developmental programs have not been defined.
Impaired embryonic proliferation and tissue development -> Abnormal facial shape INDIRECT UNKNOWN INTERMEDIATES Craniofacial patterning is affected, but the cellular route is unknown.
Impaired embryonic proliferation and tissue development -> Multiple skeletal anomalies INDIRECT UNKNOWN INTERMEDIATES Limb and skeletal development can be affected through unknown intermediates.
Impaired embryonic proliferation and tissue development -> Abnormal heart morphology INDIRECT UNKNOWN INTERMEDIATES Congenital cardiac anomalies are variably present; their mechanism is unknown.
Impaired embryonic proliferation and tissue development -> Abnormality of skin pigmentation INDIRECT UNKNOWN INTERMEDIATES Pigmentary abnormalities are variably present; the responsible cell lineage is unknown.
Impaired embryonic proliferation and tissue development -> Abnormality of the genitourinary system INDIRECT UNKNOWN INTERMEDIATES Genitourinary malformations occur in some individuals through unknown developmental intermediates.
Show evidence (2 references)
PMID:30303954 SUPPORT In Vitro
"Collectively, our results establish a critical role for the DDX11-Timeless interaction in coordinating DNA replication with sister chromatid cohesion, and have important implications for understanding the molecular basis of WABS."
Directly supports replication-coupled cohesion as the canonical model.
PMID:31935221 SUPPORT In Vitro
"Furthermore, a DNA binding DDX11 mutant failed to correct SCC in WABS cells and DDX11 deficiency reduced replication fork speed."
Connects disease-cell cohesion rescue to replication-fork slowing.
rDNA chromatin and ribosome-biogenesis developmental model
rdna_ribosome_development_model ALTERNATIVE
Evidence balance 2 support
DDX11 also binds active rDNA, interacts with UBF and RNA polymerase I, and supports rRNA transcription. DDX11 depletion shifts rDNA toward heterochromatin, suppresses rRNA synthesis, and reduces proliferation; a zebrafish knockdown model couples the same molecular readouts to growth and craniofacial abnormalities. This may act alongside the canonical cohesion mechanism, but a causal contribution to human organ-specific disease has not been demonstrated.
Pathograph links
Pathogenic DDX11 helicase dysfunction -> rDNA chromatin and RNA polymerase I transcription defect DIRECT Loss of nucleolar DDX11 binding shifts active rDNA toward heterochromatin and reduces recruitment of the RNA polymerase I machinery.
rDNA chromatin and RNA polymerase I transcription defect -> Reduced cell proliferation DIRECT Suppressed rRNA transcription reduces growth and proliferation in the cell model.
Reduced cell proliferation -> Impaired embryonic proliferation and tissue development INDIRECT UNKNOWN INTERMEDIATES Reduced cell production is proposed to impair embryonic growth and organogenesis, with tissue-specific intermediates unresolved. Intermediates: Unknown tissue-specific effects of reduced ribosome output and cell-cycle progression.
Impaired embryonic proliferation and tissue development -> Intrauterine growth retardation INDIRECT UNKNOWN INTERMEDIATES Prenatal growth failure is universal in reported individuals, but the causal tissue and cellular bottleneck are not established.
Impaired embryonic proliferation and tissue development -> Postnatal growth retardation INDIRECT UNKNOWN INTERMEDIATES Persistent growth deficiency may reflect reduced cell production and nutritional factors; their relative contributions are unknown.
Impaired embryonic proliferation and tissue development -> Congenital microcephaly INDIRECT UNKNOWN INTERMEDIATES Reduced prenatal brain growth is plausibly downstream of impaired development, but neural progenitor-specific causality has not been tested.
Impaired embryonic proliferation and tissue development -> Abnormal brain morphology INDIRECT UNKNOWN INTERMEDIATES Structural brain anomalies occur in a minority of affected individuals, but their lineage-specific developmental mechanism remains unknown.
Impaired embryonic proliferation and tissue development -> Abnormal cortical gyration INDIRECT UNKNOWN INTERMEDIATES Poor sulcation, delayed gyration, and focal lissencephaly implicate cortical development through untested neural-progenitor intermediates.
Impaired embryonic proliferation and tissue development -> Hypoplasia of the corpus callosum INDIRECT UNKNOWN INTERMEDIATES Callosal hypoplasia is plausibly developmental, but no DDX11-dependent axon-guidance or commissural-neuron mechanism has been demonstrated.
Impaired embryonic proliferation and tissue development -> Cerebellar vermis hypoplasia INDIRECT UNKNOWN INTERMEDIATES Vermian hypoplasia is reported clinically, but the affected progenitor population and causal molecular branch are unresolved.
Impaired embryonic proliferation and tissue development -> Congenital sensorineural hearing impairment INDIRECT UNKNOWN INTERMEDIATES Hearing impairment reflects abnormal cochlear development; the relevant embryonic cell population and molecular route from DDX11 remain unknown.
Impaired embryonic proliferation and tissue development -> Cochlear malformation INDIRECT UNKNOWN INTERMEDIATES The tissue-selective basis of cochlear hypoplasia is unresolved.
Impaired embryonic proliferation and tissue development -> Intellectual disability INDIRECT UNKNOWN INTERMEDIATES Cognitive impairment is associated with congenital brain growth and hearing-language effects, but its direct cellular mechanism is unknown.
Impaired embryonic proliferation and tissue development -> Delayed speech and language development INDIRECT KNOWN INTERMEDIATES Severe hearing impairment is a known contributor to speech delay, while intellectual disability may additionally limit receptive language. Intermediates: Congenital sensorineural hearing impairment and limited auditory input.
Impaired embryonic proliferation and tissue development -> Global developmental delay INDIRECT UNKNOWN INTERMEDIATES Mild developmental delay is variably present; affected developmental programs have not been defined.
Impaired embryonic proliferation and tissue development -> Abnormal facial shape INDIRECT UNKNOWN INTERMEDIATES Craniofacial patterning is affected, but the cellular route is unknown.
Impaired embryonic proliferation and tissue development -> Multiple skeletal anomalies INDIRECT UNKNOWN INTERMEDIATES Limb and skeletal development can be affected through unknown intermediates.
Impaired embryonic proliferation and tissue development -> Abnormal heart morphology INDIRECT UNKNOWN INTERMEDIATES Congenital cardiac anomalies are variably present; their mechanism is unknown.
Impaired embryonic proliferation and tissue development -> Abnormality of skin pigmentation INDIRECT UNKNOWN INTERMEDIATES Pigmentary abnormalities are variably present; the responsible cell lineage is unknown.
Impaired embryonic proliferation and tissue development -> Abnormality of the genitourinary system INDIRECT UNKNOWN INTERMEDIATES Genitourinary malformations occur in some individuals through unknown developmental intermediates.
Show evidence (2 references)
PMID:26089203 SUPPORT In Vitro
"DDX11 knockdown changed the epigenetic state of rDNA loci from euchromatic structures to more heterochromatic structures, reduced the activity of UBF, decreased the recruitment of UBF and RPA194 (a subunit of Pol I) to rDNA promoter, suppressed rRNA transcription and thereby inhibited growth and..."
Establishes the rDNA-transcription and proliferation branch in cells.
PMID:26089203 SUPPORT Model Organism
"These growth disruptions in zebrafish in response to DDX11 reduction showed similarities to the clinically described developmental abnormalities found in WABS patients for the first time in any vertebrate."
Provides in-vivo developmental support, but only in a morpholino model and without proving the same pathway causes human manifestations.
?

Discussions and Knowledge Gaps

4
Which DDX11-dependent cellular defect causes each organ-specific human manifestation: replication-fork slowing, failed cohesion, altered chromatin and transcription, impaired rRNA synthesis, or a combination?
KNOWLEDGE GAP OPEN organ_specific_developmental_bridge
Attached to
pathophysiology#Slowed replication forks and defective replication-coupled cohesin loading pathophysiology#rDNA chromatin and RNA polymerase I transcription defect pathophysiology#Impaired embryonic proliferation and tissue development
The fork/cohesion and rDNA branches are experimentally reproducible, but no disease-relevant human neural, cochlear, cardiac, or embryonic model connects either branch to the defining congenital phenotype. Resolving this bridge is necessary before any organ-specific mechanism or disease-modifying target can be considered established.
Show evidence (1 reference)
PMID:26089203 SUPPORT Model Organism
"These growth disruptions in zebrafish in response to DDX11 reduction showed similarities to the clinically described developmental abnormalities found in WABS patients for the first time in any vertebrate."
Demonstrates partial model convergence but not the human organ-specific causal bridge, which is why the item remains open.
Can a stable allelic animal or human developmental model reproduce the survivable, tissue-selective phenotype of human WABS rather than the early lethality of complete Ddx11 loss or the limitations of morpholino knockdown?
KNOWLEDGE GAP OPEN complete_loss_model_mismatch
Attached to
pathophysiology#Pathogenic DDX11 helicase dysfunction pathophysiology#Impaired embryonic proliferation and tissue development
The null mouse demonstrates gene necessity but dies before relevant organ phenotypes can be assessed, while the zebrafish model is transient and only partially phenocopies WABS. Patient-variant knock-in models, ideally with lineage-resolved neural and inner-ear readouts, are needed.
Show evidence (1 reference)
PMID:17611414 SUPPORT Model Organism
"The absence of Ddx11 resulted in embryonic lethality at E10.5."
Defines the central severity mismatch of the available mouse model.
What are the adult natural history, malignancy risk, treatment toxicities, and evidence-based surveillance needs of people with biallelic DDX11 disease and of heterozygous carriers?
KNOWLEDGE GAP OPEN natural_history_and_malignancy_risk
Attached to
phenotypes#Seizure
Published cohorts are small, most affected individuals are children, and no consensus tumor-screening protocol exists. A longitudinal registry is needed to distinguish true late complications from isolated observations and to assess whether DNA-damaging therapies require special precautions.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"Surveillance: Monitor growth, speech development, and educational needs with each visit; behavioral assessment for ADHD as needed; there is no consensus regarding tumor screening."
Documents the current surveillance scope and tumor-screening uncertainty.
Does DDX11 deficiency reproducibly activate a SERF1B-SNCA aggregation pathway that contributes to impaired neuronal migration and neurodevelopment in WABS?
EMERGING HYPOTHESIS UNDER DISCUSSION serf1b_snca_neurotoxicity_model
Attached to
phenotypes#Congenital microcephaly phenotypes#Intellectual disability phenotypes#Seizure
A 2026 study reported this pathway using variants from one family, a transfected neural-cell model, RNA sequencing, and validation in fetal tissue. Independent patient-derived neural models, protein-aggregation measurements, genetic rescue, and replication across alleles are needed before it can enter the core disease graph.
Show evidence (1 reference)
PMID:42107920 SUPPORT In Vitro
"RNA-seq revealed marked upregulation of SERF1B, which was validated in fetal tissue. Mechanistically, SERF1B overexpression may accelerate SNCA protein aggregation and exacerbate neurotoxicity."
States the newly proposed molecular pathway and its limited validation.
⚙

Pathophysiology

8
Pathogenic DDX11 helicase dysfunction
Biallelic pathogenic DDX11 variants reduce functional DDX11 dosage or impair its DNA binding, ATP hydrolysis, and 5-prime-to-3-prime helicase activity. The directly assayed p.Arg263Gln WABS allele is a hypomorphic example; the degree and molecular nature of dysfunction vary across alleles.
rDNA chromatin and ribosome-biogenesis developmental model Replication-coupled cohesion and genome-maintenance model
DDX11 hgnc:2736 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves DDX11 (hgnc:2736). hgnc:2736 is a gene from the HUGO Gene Nomenclature Committee.
DNA helicase activity GO:0003678 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased DNA helicase activity (GO:0003678). GO:0003678 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Slowed replication forks and defective replication-coupled cohesin loading Loss of DDX11 DNA binding and fork-localized function slows forks and compromises recruitment or stabilization of cohesin during replication. Replication-coupled cohesion and genome-maintenance model
Variable cross-link-induced chromosome breakage DDX11-deficient cells can become hypersensitive to DNA cross-linking stress, although this phenotype is not penetrant across all affected individuals. Replication-coupled cohesion and genome-maintenance model
rDNA chromatin and RNA polymerase I transcription defect Loss of nucleolar DDX11 binding shifts active rDNA toward heterochromatin and reduces recruitment of the RNA polymerase I machinery. rDNA chromatin and ribosome-biogenesis developmental model
Show evidence (1 reference)
PMID:23033317 SUPPORT In Vitro
"Biochemical studies of purified recombinant DDX11 indicated that the p.R263Q mutation impaired DDX11 helicase activity by perturbing its DNA binding and DNA-dependent ATP hydrolysis."
Direct biochemical evidence that a WABS allele impairs DDX11 activity.
Slowed replication forks and defective replication-coupled cohesin loading
DDX11 localizes to nascent DNA, interacts with the fork-protection component Timeless, and promotes cohesin association with replication forks. DDX11 deficiency reduces fork speed; loss of this replication-coupled function compromises establishment of sister chromatid cohesion.
Replication-coupled cohesion and genome-maintenance model
replication fork processing GO:0031297 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal replication fork processing (GO:0031297). GO:0031297 is a biological process from the Gene Ontology. ⚠ ABNORMAL sister chromatid cohesion GO:0007062 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased sister chromatid cohesion (GO:0007062). GO:0007062 is a biological process from the Gene Ontology. ↓ DECREASED
replication fork GO:0005657 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves replication fork (GO:0005657). GO:0005657 is a cellular component from the Gene Ontology.
Downstream
Sister chromatid cohesion defect Failure to couple cohesin to DNA replication reduces functional cohesion. Replication-coupled cohesion and genome-maintenance model
Show evidence (2 references)
PMID:30303954 SUPPORT In Vitro
"Moreover, we found that DDX11 promotes cohesin binding to the DNA replication forks in concert with Timeless and that recombinant purified cohesin interacts with DDX11 in vitro."
Directly establishes the fork-localized cohesin-loading function.
PMID:31935221 SUPPORT In Vitro
"We found that WABS-derived cells predominantly rely on ESCO2, not ESCO1, for residual SCC, growth and survival."
Defines the residual ESCO2-dependent cohesion state in WABS cells.
Sister chromatid cohesion defect
Patient cells exhibit reduced sister chromatid cohesion. This is the consistent cytogenetic core of DDX11-related cohesinopathy and should not be conflated with the more variable induced-breakage phenotype.
Replication-coupled cohesion and genome-maintenance model
sister chromatid cohesion GO:0007062 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased sister chromatid cohesion (GO:0007062). GO:0007062 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Premature chromatid separation and railroad chromosome morphology Insufficient cohesion permits premature separation of chromatids and centromeres, producing the characteristic railroad-track appearance. Replication-coupled cohesion and genome-maintenance model
Impaired embryonic proliferation and tissue development A developmental consequence is plausible from animal loss-of-function models, but the relevant human tissues and intervening mechanisms are unknown. Replication-coupled cohesion and genome-maintenance model
Show evidence (2 references)
PMID:20137776 SUPPORT In Vitro
"The DDX11-deficient patient represents another cohesinopathy, besides Cornelia de Lange syndrome and Roberts syndrome, and shows that DDX11 functions at the interface between DNA repair and sister chromatid cohesion."
Establishes the patient-cell cohesion phenotype and DDX11 role.
PMID:30469382 SUPPORT Human Clinical
"While sister chromatid cohesion defects were observed in all the patients described so far, two of these novel WABS patients do not display drug-induced elevated chromosomal breakage."
Supports treating cohesion failure as the consistent cellular signature while keeping induced breakage explicitly variable.
Premature chromatid separation and railroad chromosome morphology
Premature chromatid separation, premature centromere division, centromeric heterochromatin repulsion, and railroad-track chromosomes are characteristic cytogenetic manifestations of the cohesion defect. Unlike induced breakage, this cohesion-related morphology is central to distinguishing WABS from Fanconi anemia.
chromosome segregation GO:0007059 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal chromosome segregation (GO:0007059). GO:0007059 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (1 reference)
PMID:21490908 SUPPORT Human Clinical
"This complication may be avoided by scoring metaphase chromosomes-in addition to chromosomal breakage-for spontaneously occurring premature centromere division, which is characteristic for RBS and WABS, but not for FA."
Supports both the cytogenetic signature and its diagnostic value.
rDNA chromatin and RNA polymerase I transcription defect
In DDX11-depleted HeLa cells, active rDNA becomes more heterochromatic, recruitment of UBF and RNA polymerase I falls, and rRNA transcription is suppressed. WABS-derived mutant proteins show reduced rDNA-promoter binding and ATPase activity. The cell biology is experimentally supported, but its causal contribution to human WABS remains provisional.
rDNA chromatin and ribosome-biogenesis developmental model
heterochromatin organization GO:0070828 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal heterochromatin organization (GO:0070828). GO:0070828 is a biological process from the Gene Ontology. ⚠ ABNORMAL ribosome biogenesis GO:0042254 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased ribosome biogenesis (GO:0042254). GO:0042254 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Reduced cell proliferation Suppressed rRNA transcription reduces growth and proliferation in the cell model. rDNA chromatin and ribosome-biogenesis developmental model
Show evidence (1 reference)
PMID:26089203 SUPPORT In Vitro
"R263Q and K897del, and a Fe-S deletion construct demonstrated significantly reduced binding abilities to rDNA promoters and lowered DNA-dependent ATPase activities compared with wild-type DDX11."
Extends the rDNA defect from knockdown to two WABS-derived proteins.
Reduced cell proliferation
DDX11 depletion reduces proliferation in cultured cells. A similar reduction in developmental cell production could contribute to growth restriction and microcephaly, but this extrapolation has not been demonstrated in relevant human embryonic tissues.
rDNA chromatin and ribosome-biogenesis developmental model
Downstream
Impaired embryonic proliferation and tissue development Reduced cell production is proposed to impair embryonic growth and organogenesis, with tissue-specific intermediates unresolved. rDNA chromatin and ribosome-biogenesis developmental model
Show evidence (1 reference)
PMID:26089203 SUPPORT In Vitro
"suppressed rRNA transcription and thereby inhibited growth and proliferation of HeLa cells."
Directly supports reduced proliferation in the depletion model.
Impaired embryonic proliferation and tissue development
The cellular mechanisms are proposed to converge on impaired embryonic proliferation and organogenesis. Ddx11-null mice and DDX11-knockdown zebrafish establish developmental requirements for the gene, but neither model identifies the human tissue-specific intermediates that yield the clinical triad. This node and its phenotype edges are therefore explicitly hypothetical.
rDNA chromatin and ribosome-biogenesis developmental model Replication-coupled cohesion and genome-maintenance model
Downstream
Intrauterine growth retardation Prenatal growth failure is universal in reported individuals, but the causal tissue and cellular bottleneck are not established. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Postnatal growth retardation Persistent growth deficiency may reflect reduced cell production and nutritional factors; their relative contributions are unknown. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Congenital microcephaly Reduced prenatal brain growth is plausibly downstream of impaired development, but neural progenitor-specific causality has not been tested. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Abnormal brain morphology Structural brain anomalies occur in a minority of affected individuals, but their lineage-specific developmental mechanism remains unknown. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Abnormal cortical gyration Poor sulcation, delayed gyration, and focal lissencephaly implicate cortical development through untested neural-progenitor intermediates. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Hypoplasia of the corpus callosum Callosal hypoplasia is plausibly developmental, but no DDX11-dependent axon-guidance or commissural-neuron mechanism has been demonstrated. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Cerebellar vermis hypoplasia Vermian hypoplasia is reported clinically, but the affected progenitor population and causal molecular branch are unresolved. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Congenital sensorineural hearing impairment Hearing impairment reflects abnormal cochlear development; the relevant embryonic cell population and molecular route from DDX11 remain unknown. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Cochlear malformation The tissue-selective basis of cochlear hypoplasia is unresolved. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Intellectual disability Cognitive impairment is associated with congenital brain growth and hearing-language effects, but its direct cellular mechanism is unknown. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Delayed speech and language development Severe hearing impairment is a known contributor to speech delay, while intellectual disability may additionally limit receptive language. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Global developmental delay Mild developmental delay is variably present; affected developmental programs have not been defined. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Abnormal facial shape Craniofacial patterning is affected, but the cellular route is unknown. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Multiple skeletal anomalies Limb and skeletal development can be affected through unknown intermediates. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Abnormal heart morphology Congenital cardiac anomalies are variably present; their mechanism is unknown. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Abnormality of skin pigmentation Pigmentary abnormalities are variably present; the responsible cell lineage is unknown. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Abnormality of the genitourinary system Genitourinary malformations occur in some individuals through unknown developmental intermediates. Replication-coupled cohesion and genome-maintenance model rDNA chromatin and ribosome-biogenesis developmental model
Show evidence (2 references)
PMID:17611414 SUPPORT Model Organism
"The absence of Ddx11 resulted in embryonic lethality at E10.5."
Shows that Ddx11 is required for mammalian embryonic development.
PMID:26089203 SUPPORT Model Organism
"These growth disruptions in zebrafish in response to DDX11 reduction showed similarities to the clinically described developmental abnormalities found in WABS patients for the first time in any vertebrate."
Shows partial developmental phenocopy after DDX11 reduction.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Warsaw breakage syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

18
Cardiovascular 1
Abnormal heart morphology FREQUENT HP:0001627 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal heart morphology (HP:0001627). HP:0001627 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"are reported in 33% (7/21 individuals). These include patent ductus arteriosus (1), small atrial septal defect with large patent ductus arteriosus (1), ventricular septal defect (4), and tetralogy of Fallot (1)."
Provides the available cohort frequency.
Genitourinary 1
Abnormality of the genitourinary system HP:0000119 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the genitourinary system (HP:0000119). HP:0000119 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"Abnormal skin pigmentation and genitourinary malformations have also been reported."
Supports genitourinary malformations as part of the reported spectrum.
Head and Neck 2
Congenital microcephaly OBLIGATE HP:0000252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Microcephaly (HP:0000252), qualified as severity severe; antenatal onset. HP:0000252 is a phenotype from the Human Phenotype Ontology.
Severity: SEVERE Onset: ANTENATAL
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"has a prenatal onset and is reported in all affected individuals. Congenital microcephaly can range from 3.3 to 10 standard deviations (SD) below the mean for age and sex."
Establishes prenatal onset and reported universality.
Abnormal facial shape HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28960803 SUPPORT Human Clinical
"The sisters reported here display the distinguishing clinical features of WABS: pre- and post-natal growth restriction, microcephaly, intellectual disability, sensorineural hearing loss with cochlear abnormalities, and facial dysmorphic features."
Documents facial dysmorphism in two molecularly confirmed siblings.
Integument 1
Abnormality of skin pigmentation HP:0001000 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of skin pigmentation (HP:0001000). HP:0001000 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:25701697 SUPPORT Human Clinical
"In our case the patient exhibited a chronic rash of livedo reticularis with telangiectasia on her legs. Abnormally pigmented lesions and cutis mamorata were reported in the original WABS case."
Documents the spectrum and recurrence of cutaneous pigmentation findings.
Musculoskeletal 1
Multiple skeletal anomalies FREQUENT HP:0005775 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Multiple skeletal anomalies (HP:0005775). HP:0005775 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"are commonly seen (16/23 individuals), including proximal insertion of thumbs, shortened first metacarpals, small radii, syndactyly, and short thumbs."
Quantifies skeletal involvement and provides representative findings.
PMID:28960803 SUPPORT Human Clinical
"In addition, our cases had early menarche at 8 and 10 years of age, bilateral small thumbs, and the younger, more severely affected sister had small fibulae."
Extends the limb phenotype to small thumbs and fibulae.
Nervous System 6
Hypoplasia of the corpus callosum HP:0002079 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypoplasia of the corpus callosum (HP:0002079). HP:0002079 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"Eight individuals presented with brain anomalies including focal poor sulcation pattern, delayed gyration, focal lissencephaly, corpus callosum hypoplasia, and cerebellar vermis hypoplasia"
Directly includes corpus callosum hypoplasia in the reported spectrum.
Cerebellar vermis hypoplasia HP:0001320 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar vermis hypoplasia (HP:0001320). HP:0001320 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"Eight individuals presented with brain anomalies including focal poor sulcation pattern, delayed gyration, focal lissencephaly, corpus callosum hypoplasia, and cerebellar vermis hypoplasia"
Directly includes cerebellar vermis hypoplasia in the reported spectrum.
Intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249), qualified as course stable. HP:0001249 is a phenotype from the Human Phenotype Ontology.
Course: STABLE
Show evidence (3 references)
PMID:31169992 SUPPORT Human Clinical
"Intellectual disability is typically in the mild-to-moderate range."
Describes the usual severity.
PMID:30924321 SUPPORT Human Clinical
"These findings further extend the clinical and molecular knowledge about the WABS showing a possible mild phenotype without major malformations or intellectual disability."
Establishes that intellectual disability is not obligate.
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"<b>Intellectual disability and developmental delay</b> range from mild to moderate and tend to be stable."
Directly supports the typical stable clinical course.
Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"Severe speech delay is common."
Directly supports speech delay as a common feature.
Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263), qualified as course stable. HP:0001263 is a phenotype from the Human Phenotype Ontology.
Course: STABLE
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"range from mild to moderate and tend to be stable. Gross and fine motor milestones are usually attained at the usual time although a few individuals have mild delays."
Directly supports developmental delay while calibrating its typical course.
Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41853675 SUPPORT Human Clinical
"A literature review identified a total of 7 previously reported children with WABS complicated by epilepsy, and we collected and summarized their clinical and genetic information."
Documents recurrence of epilepsy beyond a single patient.
Growth 2
Intrauterine growth retardation OBLIGATE HP:0001511 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intrauterine growth retardation (HP:0001511). HP:0001511 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"All 26 reported individuals to date had intrauterine growth deficiency with birth weight and height below the third centile."
Provides the reported frequency and severity of prenatal growth deficiency.
Postnatal growth retardation OBLIGATE HP:0008897 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Postnatal growth retardation (HP:0008897). HP:0008897 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"Postnatal growth deficiency was also reported in all individuals; two individuals had weights between the 50th and 75th percentile later in childhood, after they were started on gastrostomy tube feedings"
Documents persistent postnatal deficiency and possible nutritional response.
Other 4
Abnormal brain morphology FREQUENT HP:0012443 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal brain morphology (HP:0012443). HP:0012443 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"Eight individuals presented with brain anomalies including focal poor sulcation pattern, delayed gyration, focal lissencephaly, corpus callosum hypoplasia, and cerebellar vermis hypoplasia"
Supplies the numerator and the reported structural brain spectrum.
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"related cohesinopathy is rare, with 26 individuals reported to date"
Supplies the GeneReviews cohort denominator; 8 of 26 is 30.8% and maps to the FREQUENT band.
Abnormal cortical gyration HP:0002536 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal cortical gyration (HP:0002536). HP:0002536 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"Eight individuals presented with brain anomalies including focal poor sulcation pattern, delayed gyration, focal lissencephaly, corpus callosum hypoplasia, and cerebellar vermis hypoplasia"
Directly identifies cortical gyration and sulcation abnormalities.
Congenital sensorineural hearing impairment VERY_FREQUENT HP:0008527 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Congenital sensorineural hearing impairment (HP:0008527). HP:0008527 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"DDX11-related cohesinopathy is characterized by the clinical triad of severe congenital microcephaly, growth restriction, and sensorineural hearing loss due to cochlear hypoplasia."
Defines hearing loss as one arm of the core clinical triad.
Cochlear malformation VERY_FREQUENT HP:0008554 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cochlear malformation (HP:0008554). HP:0008554 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30216658 SUPPORT Human Clinical
"Although all the reported patients had cochlear hypoplasia, one patient also had posterior labyrinthine anomaly."
Documents high penetrance and variable inner-ear morphology.
🧬

Genetic Associations

1
DDX11 (Biallelic pathogenic variants are causative)
Gene: DDX11 hgnc:2736 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is DDX11 (hgnc:2736). hgnc:2736 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (3 references)
PMID:20137776 SUPPORT Human Clinical
"Here, we report a human individual with biallelic mutations in DDX11."
The founding report identifies biallelic DDX11 variants in WABS.
PMID:23033317 SUPPORT In Vitro
"Biochemical studies of purified recombinant DDX11 indicated that the p.R263Q mutation impaired DDX11 helicase activity by perturbing its DNA binding and DNA-dependent ATP hydrolysis."
Provides functional evidence for a disease-associated allele.
CGGV:assertion_99d606e6-7d37-4502-bf44-bbf2db469459-2025-02-21T170000.000Z SUPPORT Other
"DDX11 | HGNC:2736 | Warsaw breakage syndrome | MONDO:0013252 | AR | Definitive"
ClinGen classifies the autosomal recessive DDX11-WABS gene-disease relationship as definitive.
💊

Medical Actions

6
Nutritional support for poor weight gain
Category: Therapeutic Action: Nutritional SupportNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Nutritional Support (NCIT:C15433). NCIT:C15433 is a clinical intervention from the NCI Thesaurus. NCIT:C15433
Optimize nutrition for poor weight gain; supplementary formula and gastrostomy feeding can be used when needed. This is supportive care and does not correct the underlying DDX11 defect.
Target Phenotypes: Postnatal growth retardation HP:0008897 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Postnatal growth retardation (HP:0008897). HP:0008897 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"Supplementary formula and/or gastrostomy tube as needed to optimize nutrition."
Provides the GeneReviews nutrition recommendation.
Hearing habilitation and communication support
Category: Therapeutic Action: RehabilitationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Rehabilitation (NCIT:C15315). NCIT:C15315 is a clinical intervention from the NCI Thesaurus. NCIT:C15315
Management depends on residual cochlear and cochlear-nerve anatomy and can include hearing aids, cochlear implantation when a cochlear nerve is present, or an auditory brainstem implant for profound loss with absent or nonfunctioning cochlea or auditory nerve. Communication support should begin promptly and may include sign language, auditory therapy, speech-language therapy, and hearing-focused education.
Target Phenotypes: Congenital sensorineural hearing impairment HP:0008527 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Congenital sensorineural hearing impairment (HP:0008527). HP:0008527 is a phenotype from the Human Phenotype Ontology. Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"Treatments for hearing loss include hearing aids; cochlear implantation; auditory brain stem implant for individuals with profound hearing loss due to missing or nonfunctioning cochlea or auditory nerve; establishing a system of communication and hearing habilitation that may include sign..."
Directly supports the anatomy-dependent hearing and communication options.
Early developmental and educational intervention
Category: Therapeutic Action: Early InterventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Early Intervention (NCIT:C159524). NCIT:C159524 is a clinical intervention from the NCI Thesaurus. NCIT:C159524
Provide early intervention and individualized educational support, with physical, occupational, and speech-language therapy according to need.
Target Phenotypes: Intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology. Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology. Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"Early intervention and educational support; physical, occupational, and speech therapies"
States the recommended developmental supports.
Organ-specific specialist management
Category: Therapeutic Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Treat congenital cardiac anomalies with cardiology, limb anomalies with orthopedics and occupational therapy, and genitourinary anomalies with nephrology or urology. Management is individualized and supportive.
Target Phenotypes: Abnormal heart morphology HP:0001627 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Abnormal heart morphology (HP:0001627). HP:0001627 is a phenotype from the Human Phenotype Ontology. Multiple skeletal anomalies HP:0005775 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Multiple skeletal anomalies (HP:0005775). HP:0005775 is a phenotype from the Human Phenotype Ontology. Abnormality of the genitourinary system HP:0000119 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Abnormality of the genitourinary system (HP:0000119). HP:0000119 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"treatment of cardiac anomalies per cardiologist; treatment of limb anomalies per orthopedist with occupational therapy as needed; treatment of genitourinary anomalies per nephrologist and/or urologist."
Directly supports specialist-directed supportive management.
Growth, development, and behavior surveillance
Category: Monitoring Action: Clinical EvaluationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Clinical Evaluation (NCIT:C124351). NCIT:C124351 is a clinical intervention from the NCI Thesaurus. NCIT:C124351
Measure height, weight, head circumference, and body mass index and review speech development and educational needs at every visit. Assess for ADHD or other behavioral concerns when clinically indicated. There is no consensus for tumor screening because malignancy risk remains unproven.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"Monitor growth, speech development, and educational needs with each visit; behavioral assessment for ADHD as needed; there is no consensus regarding tumor screening."
States the longitudinal surveillance recommendations and tumor-screening uncertainty.
Genetic counseling and reproductive testing
Category: Counseling / Informational Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Counsel families about autosomal recessive inheritance and the 25% recurrence risk when both parents carry a pathogenic variant. Once familial DDX11 variants are known, offer carrier testing to at-risk relatives and discuss prenatal and preimplantation genetic testing.
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"Once the DDX11 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible."
Supports cascade and reproductive testing after familial variant identification.
🔬

Diagnosis

3
Clinical recognition of the core triad
Suspect DDX11-related cohesinopathy in an individual with severe congenital microcephaly, prenatal and postnatal growth restriction, and congenital sensorineural hearing impairment caused by cochlear abnormalities. Skeletal, cardiac, pigmentary, genitourinary, and cytogenetic findings can support the suspicion, but no consensus clinical diagnostic criteria exist.
Clinical Evaluation NCIT:C124351 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"DDX11-related cohesinopathy is characterized by the clinical triad of severe congenital microcephaly, growth restriction, and sensorineural hearing loss due to cochlear hypoplasia."
Defines the clinical pattern that should trigger testing.
DDX11 molecular genetic testing
The diagnosis is established by identifying biallelic pathogenic or likely pathogenic DDX11 variants. Depending on presentation, testing may use DDX11 sequencing, an appropriate multigene panel, exome sequencing, or genome sequencing. A negative or single-variant sequence result may warrant deletion/duplication analysis; highly homologous DDX11 pseudogenes complicate assay design and interpretation.
Genetic Testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:31169992 SUPPORT Human Clinical
"The diagnosis of DDX11-related cohesinopathy is established in a proband with biallelic pathogenic variants in DDX11 identified by molecular genetic testing."
Directly states the molecular diagnostic criterion.
Supportive cytogenetic analysis
C-banded metaphase analysis can show premature chromatid separation, premature centromere division, and railroad chromosomes. DEB- or MMC-treated lymphocytes can show increased breaks and radial forms, but this induced breakage is variable and can be absent; a normal breakage assay therefore cannot exclude WABS, and molecular confirmation remains necessary.
Karyotyping NCIT:C16768 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:21490908 SUPPORT Human Clinical
"This complication may be avoided by scoring metaphase chromosomes-in addition to chromosomal breakage-for spontaneously occurring premature centromere division, which is characteristic for RBS and WABS, but not for FA."
Supports scoring cohesion morphology during the cytogenetic differential.
PMID:30216658 SUPPORT Human Clinical
"We conclude that while the cardinal clinical features in WBS (microcephaly, growth retardation, and cochlear anomalies) are almost universally present, the breakage phenotype is highly variable and can be absent in some cases."
Establishes that absence of induced breakage does not exclude WABS.
📈

Progression

2
Prenatal presentation
Age: Fetal period to birth
Growth restriction and microcephaly begin prenatally. Reported fetal imaging can additionally show delayed sulcation, a short corpus callosum, or cerebellar vermis hypoplasia, but these brain findings are variable rather than defining.
Show evidence (2 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"has a prenatal onset and is reported in all affected individuals. Congenital microcephaly can range from 3.3 to 10 standard deviations (SD) below the mean for age and sex."
Establishes prenatal onset of the cardinal microcephaly.
PMID:39428552 SUPPORT Human Clinical
"We report a case of prenatal diagnosis of WABS in a 24-week gestation fetus exhibiting microcephaly, delayed sulcation, short corpus callosum, cerebellar vermis hypoplasia and intrahepatic portal-systemic shunts."
Documents the expanded prenatal imaging spectrum in one fetus.
Childhood growth and neurodevelopment
Age: Infancy through childhood
Postnatal growth deficiency persists. Intellectual disability and developmental delay are usually mild to moderate and tend to remain stable; motor milestones are often acquired on time, while expressive language is disproportionately affected by congenital hearing loss. Mild presentations without major malformations or intellectual disability have been reported.
Show evidence (2 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"range from mild to moderate and tend to be stable. Gross and fine motor milestones are usually attained at the usual time although a few individuals have mild delays."
Describes the typical childhood neurodevelopmental course.
PMID:30924321 SUPPORT Human Clinical
"These findings further extend the clinical and molecular knowledge about the WABS showing a possible mild phenotype without major malformations or intellectual disability."
Documents clinically milder disease in two affected sisters.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
The 2025 GeneReviews update counted 26 molecularly confirmed individuals reported through 2024. Further case-based publications appeared in 2026, so 26 is a dated literature count rather than a current census or a population prevalence estimate; overlapping reports also cannot be assumed to describe distinct individuals. Ascertainment is likely incomplete because the syndrome is very rare, its breakage phenotype may be absent, and its clinical features overlap other chromosome-instability disorders.
Show evidence (4 references)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"related cohesinopathy is rare, with 26 individuals reported to date"
Documents the literature count in the 2025 GeneReviews update.
PMID:30216658 SUPPORT Human Clinical
"We conclude that while the cardinal clinical features in WBS (microcephaly, growth retardation, and cochlear anomalies) are almost universally present, the breakage phenotype is highly variable and can be absent in some cases."
Supports the ascertainment caveat: absence of a breakage phenotype can obscure recognition, but the study does not quantify underdiagnosis.
PMID:41853675 SUPPORT Human Clinical
"We present a boy exhibiting the core manifestations of this syndrome."
Documents a case-based WABS publication after the GeneReviews literature count.
+ 1 more reference
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Warsaw breakage syndrome:

Fanconi anemia MONDO:0019391
Overlapping Features Fanconi anemia overlaps through prenatal growth deficiency, microcephaly, limb and pigmentary anomalies, and cross-linker-induced chromosome breakage. Progressive bone-marrow failure and pancytopenia favor Fanconi anemia; congenital sensorineural hearing impairment with cochlear hypoplasia and spontaneous premature centromere division favor DDX11-related cohesinopathy.
Distinguishing Features
  • Progressive bone-marrow failure with pancytopenia is characteristic of Fanconi anemia.
  • Hearing loss in Fanconi anemia is usually conductive rather than the congenital sensorineural loss of WABS.
  • Premature centromere division is characteristic of WABS and Roberts syndrome but not Fanconi anemia.
Show evidence (1 reference)
PMID:21490908 SUPPORT Human Clinical
"This complication may be avoided by scoring metaphase chromosomes-in addition to chromosomal breakage-for spontaneously occurring premature centromere division, which is characteristic for RBS and WABS, but not for FA."
Gives the key cytogenetic discriminator from Fanconi anemia.
Roberts-SC phocomelia syndrome Not Yet Curated MONDO:0100253
Overlapping Features ESCO2-related Roberts syndrome is another autosomal recessive cohesinopathy with prenatal growth restriction, limb anomalies, and premature centromere separation. Bilateral symmetric tetraphocomelia or hypomelia, contractures, ear malformations, and corneal opacities favor Roberts syndrome; congenital sensorineural hearing impairment is not characteristic.
Distinguishing Features
  • Roberts syndrome is caused by biallelic ESCO2 variants rather than DDX11 variants.
  • Severe symmetric limb reduction defects and flexion contractures favor Roberts syndrome.
  • Sensorineural hearing impairment with cochlear hypoplasia favors WABS.
Show evidence (1 reference)
PMID:20137776 SUPPORT Human Clinical
"Defective DDX11 is associated with a unique cellular phenotype in which features of Fanconi anemia (drug-induced chromosomal breakage) and Roberts syndrome (sister chromatid cohesion defects) coexist."
Establishes the cohesion-based overlap with Roberts syndrome.
Nijmegen breakage syndrome MONDO:0009623
Overlapping Features Nijmegen breakage syndrome overlaps through microcephaly, growth deficiency, and chromosome instability. Progressive microcephaly, immunodeficiency, characteristic chromosome 7/14 rearrangements, premature ovarian failure, and lymphoma risk favor Nijmegen breakage syndrome; sensorineural hearing impairment is not typical.
Distinguishing Features
  • Immunodeficiency and marked lymphoma predisposition favor Nijmegen breakage syndrome.
  • Chromosome 7 and 14 inversions or translocations favor Nijmegen breakage syndrome.
  • Congenital cochlear hypoplasia and sensorineural hearing impairment favor WABS.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"Chromosome instability (inversions &#x00026; translocations involving chromosomes 7 &#x00026; 14)"
Provides a specific cytogenetic discriminator for Nijmegen breakage syndrome.
Microcephalic osteodysplastic primordial dwarfism type II MONDO:0008872
Overlapping Features PCNT-related microcephalic osteodysplastic primordial dwarfism type II overlaps through severe microcephaly and pre- and postnatal growth deficiency. More extreme short stature, central-nervous-system vascular anomalies, insulin resistance, and absence of cochlear hypoplasia favor the primordial-dwarfism diagnosis.
Distinguishing Features
  • Growth deficiency and short stature are generally more severe in MOPD II.
  • CNS vascular anomalies and insulin resistance favor MOPD II.
  • Cochlear hypoplasia and the WABS cohesion phenotype are absent from MOPD II.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK541972/ SUPPORT Human Clinical
"Growth deficiency is more severe; extremely short stature"
Provides a principal clinical discriminator for MOPD II.
🧫

Experimental Models

2
Patient-derived lymphocyte and lymphoblastoid cell models PRIMARY_CELL_CULTURE
Patient cells reveal the disease-proximal cytogenetic phenotype: sister chromatid cohesion defects, premature centromere division, and in some individuals cross-linker-induced chromosome breakage. WABS-derived cells also show reduced replication-fork speed and dependence on residual ESCO2-mediated cohesion. The platform is strong for cell-autonomous genome-maintenance mechanisms but cannot reproduce organogenesis or neural and cochlear tissue selectivity.
Organism
Homo sapiens NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
Primary T lymphocytes and Epstein-Barr-virus-immortalized B-lymphoblastoid lines from molecularly confirmed affected individuals
Show evidence (2 references)
PMID:20137776 SUPPORT In Vitro
"Defective DDX11 is associated with a unique cellular phenotype in which features of Fanconi anemia (drug-induced chromosomal breakage) and Roberts syndrome (sister chromatid cohesion defects) coexist."
Establishes the core patient-cell model readouts.
PMID:31935221 SUPPORT In Vitro
"We found that WABS-derived cells predominantly rely on ESCO2, not ESCO1, for residual SCC, growth and survival."
Supports ESCO2 dependence as an experimentally tractable patient-cell phenotype.
DDX11-depleted and complementation human cell-line models CELL_LINE
Engineered human cells resolve two experimentally separable functions: DDX11-Timeless-dependent recruitment of cohesin at replication forks, and nucleolar DDX11-dependent maintenance of active rDNA and RNA polymerase I transcription. These systems establish cellular mechanisms but are not patient-derived developmental tissue models.
Organism
Homo sapiens NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
HeLa and other human cell lines with DDX11 depletion, mutant complementation, or Timeless-interaction perturbation
Show evidence (2 references)
PMID:30303954 SUPPORT In Vitro
"We demonstrated that DDX11 interacts with Timeless, a component of the replication fork-protection complex, through a conserved peptide motif."
Establishes the engineered-cell fork/cohesion mechanism.
PMID:26089203 SUPPORT In Vitro
"DDX11 knockdown changed the epigenetic state of rDNA loci from euchromatic structures to more heterochromatic structures, reduced the activity of UBF, decreased the recruitment of UBF and RPA194 (a subunit of Pol I) to rDNA promoter, suppressed rRNA transcription and thereby inhibited growth and..."
Establishes the engineered-cell rDNA and proliferation phenotype.
🐁

Animal Models

2
Morpholino knockdown of the zebrafish DDX11 ortholog Danio rerio
DDX11 knockdown produces growth retardation and vertebral and craniofacial malformations while reducing Pol I recruitment and nascent pre-rRNA. This is the only model linking rDNA readouts to a partial WABS-like developmental phenotype, but morpholino knockdown is not a stable allele and the model did not reproduce or assay the human cochlear and neurocognitive phenotype.
Species
Danio rerio
Genotype
Morpholino knockdown of the zebrafish DDX11 ortholog
Genes
DDX11 hgnc:2736 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns DDX11 (hgnc:2736). hgnc:2736 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:26089203 SUPPORT Model Organism
"Knockdown of the zebrafish ortholog of human DDX11 by morpholinos resulted in growth retardation and vertebral and craniofacial malformations in zebrafish, concomitant with the changes in histone epigenetic modifications at rDNA loci, the reduction of Pol I recruitment to the rDNA promoter and a..."
Defines both developmental and molecular readouts of the zebrafish model.
Homozygous Ddx11-null mouse Mus musculus
Complete Ddx11 loss causes embryonic lethality around E10.5, small malformed embryos, placental failure, G2/M delay, chromosome missegregation, reduced cohesion, and aneuploidy. It establishes an essential mammalian developmental role but is a severity mismatch for surviving humans with hypomorphic or partially functional biallelic alleles.
Species
Mus musculus
Genotype
Homozygous Ddx11-null mouse
Genes
DDX11 hgnc:2736 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns DDX11 (hgnc:2736). hgnc:2736 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:17611414 SUPPORT Model Organism
"The absence of Ddx11 resulted in embryonic lethality at E10.5."
Establishes the survival phenotype of complete murine loss.
PMID:17611414 SUPPORT Model Organism
"Detailed analysis of cells isolated from Ddx11-/- embryos revealed a G2/M cell cycle delay, an increased frequency of chromosome missegregation, decreased chromosome cohesion, and increased aneuploidy."
Defines the cohesion and genome-segregation readouts in the mouse model.
{ }

Source YAML

click to show 
name: Warsaw breakage syndrome
creation_date: "2026-04-15T00:00:00Z"
description: >-
  Warsaw breakage syndrome (WABS), also called DDX11-related cohesinopathy, is
  an ultra-rare autosomal recessive developmental disorder caused by biallelic
  pathogenic variants in DDX11. Its core clinical triad is congenital severe
  microcephaly, prenatal and postnatal growth restriction, and congenital
  sensorineural hearing impairment associated with cochlear hypoplasia. Sister
  chromatid cohesion defects are a consistent cellular signature, whereas
  cross-linker-induced chromosome breakage is variable and may be absent. The
  mechanistic bridge from replication-coupled cohesion failure to the
  tissue-selective developmental phenotype remains unresolved; altered rDNA
  transcription and ribosome biogenesis constitute a supported but still
  provisional additional disease mechanism.
category: Mendelian
parents:
- Neurodevelopmental disorder
- Genetic disease
synonyms:
- WABS
- Warsaw syndrome
- DDX11-related cohesinopathy
disease_term:
  preferred_term: Warsaw breakage syndrome
  term:
    id: MONDO:0013252
    label: Warsaw breakage syndrome
references:
- reference: PMID:31169992
  title: DDX11-Related Cohesinopathy.
  tags:
  - GeneReviews
- reference: PMID:20137776
  title: >-
    Warsaw breakage syndrome, a cohesinopathy associated with mutations in the
    XPD helicase family member DDX11/ChlR1.
- reference: PMID:30216658
  title: "Warsaw breakage syndrome: Further clinical and genetic delineation."
- reference: PMID:30303954
  title: >-
    Interaction of the Warsaw breakage syndrome DNA helicase DDX11 with the
    replication fork-protection factor Timeless promotes sister chromatid
    cohesion.
- reference: PMID:26089203
  title: >-
    The Warsaw breakage syndrome-related protein DDX11 is required for ribosomal
    RNA synthesis and embryonic development.

inheritance:
- name: Autosomal recessive inheritance
  description: >-
    DDX11-related cohesinopathy follows autosomal recessive inheritance. When
    both parents carry a familial pathogenic variant, each pregnancy has a 25%
    probability of an affected child, a 50% probability of an unaffected
    carrier, and a 25% probability of an unaffected non-carrier. Once the
    familial variants are known, carrier, prenatal, and preimplantation genetic
    testing are possible.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DDX11-related cohesinopathy is inherited in an autosomal recessive manner.
    explanation: Directly states the mode of inheritance.
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If both parents are known to be heterozygous for a DDX11 pathogenic
      variant, each sib of an affected individual has at conception a 25% chance
      of being affected, a 50% chance of being a carrier, and a 25% chance of
      being unaffected and not a carrier.
    explanation: Provides the recurrence risks used in genetic counseling.

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    The 2025 GeneReviews update counted 26 molecularly confirmed individuals
    reported through 2024. Further case-based publications appeared in 2026, so
    26 is a dated literature count rather than a current census or a population
    prevalence estimate; overlapping reports also cannot be assumed to describe
    distinct individuals. Ascertainment is likely incomplete because the
    syndrome is very rare, its breakage phenotype may be absent, and its clinical
    features overlap other chromosome-instability disorders.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      related cohesinopathy is rare, with 26 individuals reported to date
    explanation: Documents the literature count in the 2025 GeneReviews update.
  - reference: PMID:30216658
    reference_title: "Warsaw breakage syndrome: Further clinical and genetic delineation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that while the cardinal clinical features in WBS
      (microcephaly, growth retardation, and cochlear anomalies) are almost
      universally present, the breakage phenotype is highly variable and can be
      absent in some cases.
    explanation: >-
      Supports the ascertainment caveat: absence of a breakage phenotype can
      obscure recognition, but the study does not quantify underdiagnosis.
  - reference: PMID:41853675
    reference_title: >-
      A pediatric patient with Warsaw breakage syndrome presenting with epilepsy:
      a case report and literature review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a boy exhibiting the core manifestations of this syndrome.
    explanation: Documents a case-based WABS publication after the GeneReviews literature count.
  - reference: PMID:42107920
    reference_title: >-
      Genetic characterization of DDX11 variants identified in a Chinese family
      with Warsaw breakage syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a detailed case report of a proband with WABS.
    explanation: >-
      Documents another 2026 case-based publication; it is not added arithmetically
      to the case count because potentially overlapping reports require deduplication.

progression:
- phase: Prenatal presentation
  age_range: Fetal period to birth
  notes: >-
    Growth restriction and microcephaly begin prenatally. Reported fetal imaging
    can additionally show delayed sulcation, a short corpus callosum, or
    cerebellar vermis hypoplasia, but these brain findings are variable rather
    than defining.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      has a prenatal onset and is reported in all affected individuals.
      Congenital microcephaly can range from 3.3 to 10 standard deviations (SD)
      below the mean for age and sex.
    explanation: Establishes prenatal onset of the cardinal microcephaly.
  - reference: PMID:39428552
    reference_title: >-
      Prenatal Diagnosis of Warsaw Breakage Syndrome: Fetal Compound
      Heterozygous Variants in the DDX11 Gene Associated With Growth Restriction,
      Cerebral, and Extra-Cerebral Malformations.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report a case of prenatal diagnosis of WABS in a 24-week gestation fetus
      exhibiting microcephaly, delayed sulcation, short corpus callosum,
      cerebellar vermis hypoplasia and intrahepatic portal-systemic shunts.
    explanation: Documents the expanded prenatal imaging spectrum in one fetus.
- phase: Childhood growth and neurodevelopment
  age_range: Infancy through childhood
  notes: >-
    Postnatal growth deficiency persists. Intellectual disability and
    developmental delay are usually mild to moderate and tend to remain stable;
    motor milestones are often acquired on time, while expressive language is
    disproportionately affected by congenital hearing loss. Mild presentations
    without major malformations or intellectual disability have been reported.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      range from mild to moderate and tend to be stable. Gross and fine motor
      milestones are usually attained at the usual time although a few
      individuals have mild delays.
    explanation: Describes the typical childhood neurodevelopmental course.
  - reference: PMID:30924321
    reference_title: >-
      Two further patients with Warsaw breakage syndrome. Is a mild phenotype
      possible?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings further extend the clinical and molecular knowledge about
      the WABS showing a possible mild phenotype without major malformations or
      intellectual disability.
    explanation: Documents clinically milder disease in two affected sisters.

mechanistic_hypotheses:
- hypothesis_group_id: replication_coupled_cohesion_model
  hypothesis_label: Replication-coupled cohesion and genome-maintenance model
  status: CANONICAL
  description: >-
    The best-supported model places DDX11 at nascent DNA with the fork-protection
    factor Timeless, where it promotes cohesin association during DNA
    replication. Pathogenic DDX11 dysfunction slows replication forks and
    impairs sister chromatid cohesion, producing premature chromatid separation
    and a variable genotoxin-sensitive chromosome-instability phenotype. How
    these cellular defects produce organ-selective congenital abnormalities is
    not yet known.
  evidence:
  - reference: PMID:30303954
    reference_title: >-
      Interaction of the Warsaw breakage syndrome DNA helicase DDX11 with the
      replication fork-protection factor Timeless promotes sister chromatid
      cohesion.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Collectively, our results establish a critical role for the DDX11-Timeless
      interaction in coordinating DNA replication with sister chromatid
      cohesion, and have important implications for understanding the molecular
      basis of WABS.
    explanation: Directly supports replication-coupled cohesion as the canonical model.
  - reference: PMID:31935221
    reference_title: >-
      Non-redundant roles in sister chromatid cohesion of the DNA helicase DDX11
      and the SMC3 acetyl transferases ESCO1 and ESCO2.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Furthermore, a DNA binding DDX11 mutant failed to correct SCC in WABS cells
      and DDX11 deficiency reduced replication fork speed.
    explanation: Connects disease-cell cohesion rescue to replication-fork slowing.
- hypothesis_group_id: rdna_ribosome_development_model
  hypothesis_label: rDNA chromatin and ribosome-biogenesis developmental model
  status: ALTERNATIVE
  description: >-
    DDX11 also binds active rDNA, interacts with UBF and RNA polymerase I, and
    supports rRNA transcription. DDX11 depletion shifts rDNA toward
    heterochromatin, suppresses rRNA synthesis, and reduces proliferation; a
    zebrafish knockdown model couples the same molecular readouts to growth and
    craniofacial abnormalities. This may act alongside the canonical cohesion
    mechanism, but a causal contribution to human organ-specific disease has not
    been demonstrated.
  evidence:
  - reference: PMID:26089203
    reference_title: >-
      The Warsaw breakage syndrome-related protein DDX11 is required for
      ribosomal RNA synthesis and embryonic development.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      DDX11 knockdown changed the epigenetic state of rDNA loci from euchromatic
      structures to more heterochromatic structures, reduced the activity of UBF,
      decreased the recruitment of UBF and RPA194 (a subunit of Pol I) to rDNA
      promoter, suppressed rRNA transcription and thereby inhibited growth and
      proliferation of HeLa cells.
    explanation: Establishes the rDNA-transcription and proliferation branch in cells.
  - reference: PMID:26089203
    reference_title: >-
      The Warsaw breakage syndrome-related protein DDX11 is required for
      ribosomal RNA synthesis and embryonic development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These growth disruptions in zebrafish in response to DDX11 reduction
      showed similarities to the clinically described developmental
      abnormalities found in WABS patients for the first time in any vertebrate.
    explanation: >-
      Provides in-vivo developmental support, but only in a morpholino model and
      without proving the same pathway causes human manifestations.

pathophysiology:
- name: Pathogenic DDX11 helicase dysfunction
  biological_scale: MOLECULAR
  description: >-
    Biallelic pathogenic DDX11 variants reduce functional DDX11 dosage or impair
    its DNA binding, ATP hydrolysis, and 5-prime-to-3-prime helicase activity. The
    directly assayed p.Arg263Gln WABS allele is a hypomorphic example; the degree
    and molecular nature of dysfunction vary across alleles.
  genes:
  - preferred_term: DDX11
    term:
      id: hgnc:2736
      label: DDX11
  molecular_functions:
  - preferred_term: DNA helicase activity
    modifier: DECREASED
    term:
      id: GO:0003678
      label: DNA helicase activity
  evidence:
  - reference: PMID:23033317
    reference_title: >-
      Identification and biochemical characterization of a novel mutation in
      DDX11 causing Warsaw breakage syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Biochemical studies of purified recombinant DDX11 indicated that the
      p.R263Q mutation impaired DDX11 helicase activity by perturbing its DNA
      binding and DNA-dependent ATP hydrolysis.
    explanation: Direct biochemical evidence that a WABS allele impairs DDX11 activity.
  downstream:
  - target: Slowed replication forks and defective replication-coupled cohesin loading
    description: >-
      Loss of DDX11 DNA binding and fork-localized function slows forks and
      compromises recruitment or stabilization of cohesin during replication.
    causal_link_type: DIRECT
    hypothesis_groups:
    - replication_coupled_cohesion_model
    evidence:
    - reference: PMID:31935221
      reference_title: >-
        Non-redundant roles in sister chromatid cohesion of the DNA helicase DDX11
        and the SMC3 acetyl transferases ESCO1 and ESCO2.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Furthermore, a DNA binding DDX11 mutant failed to correct SCC in WABS
        cells and DDX11 deficiency reduced replication fork speed.
      explanation: Demonstrates both fork slowing and failed cohesion rescue after DDX11 dysfunction.
  - target: Variable cross-link-induced chromosome breakage
    description: >-
      DDX11-deficient cells can become hypersensitive to DNA cross-linking stress,
      although this phenotype is not penetrant across all affected individuals.
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - replication_coupled_cohesion_model
    evidence:
    - reference: PMID:20137776
      reference_title: >-
        Warsaw breakage syndrome, a cohesinopathy associated with mutations in
        the XPD helicase family member DDX11/ChlR1.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Defective DDX11 is associated with a unique cellular phenotype in which
        features of Fanconi anemia (drug-induced chromosomal breakage) and Roberts
        syndrome (sister chromatid cohesion defects) coexist.
      explanation: Establishes induced breakage in the founding patient-cell model.
  - target: rDNA chromatin and RNA polymerase I transcription defect
    description: >-
      Loss of nucleolar DDX11 binding shifts active rDNA toward heterochromatin
      and reduces recruitment of the RNA polymerase I machinery.
    causal_link_type: DIRECT
    hypothesis_groups:
    - rdna_ribosome_development_model
    evidence:
    - reference: PMID:26089203
      reference_title: >-
        The Warsaw breakage syndrome-related protein DDX11 is required for
        ribosomal RNA synthesis and embryonic development.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        DDX11 is a novel nucleolar protein that preferentially binds to
        hypomethylated active ribosomal DNA (rDNA) gene loci, where it interacts
        with upstream binding factor (UBF) and the RNA polymerase I (Pol I).
      explanation: Defines the direct nucleolar and rDNA role perturbed by DDX11 loss.

- name: Slowed replication forks and defective replication-coupled cohesin loading
  biological_scale: CELLULAR
  description: >-
    DDX11 localizes to nascent DNA, interacts with the fork-protection component
    Timeless, and promotes cohesin association with replication forks. DDX11
    deficiency reduces fork speed; loss of this replication-coupled function
    compromises establishment of sister chromatid cohesion.
  biological_processes:
  - preferred_term: replication fork processing
    modifier: ABNORMAL
    term:
      id: GO:0031297
      label: replication fork processing
  - preferred_term: sister chromatid cohesion
    modifier: DECREASED
    term:
      id: GO:0007062
      label: sister chromatid cohesion
  cellular_components:
  - preferred_term: replication fork
    term:
      id: GO:0005657
      label: replication fork
  evidence:
  - reference: PMID:30303954
    reference_title: >-
      Interaction of the Warsaw breakage syndrome DNA helicase DDX11 with the
      replication fork-protection factor Timeless promotes sister chromatid
      cohesion.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Moreover, we found that DDX11 promotes cohesin binding to the DNA
      replication forks in concert with Timeless and that recombinant purified
      cohesin interacts with DDX11 in vitro.
    explanation: Directly establishes the fork-localized cohesin-loading function.
  - reference: PMID:31935221
    reference_title: >-
      Non-redundant roles in sister chromatid cohesion of the DNA helicase DDX11
      and the SMC3 acetyl transferases ESCO1 and ESCO2.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We found that WABS-derived cells predominantly rely on ESCO2, not ESCO1,
      for residual SCC, growth and survival.
    explanation: Defines the residual ESCO2-dependent cohesion state in WABS cells.
  downstream:
  - target: Sister chromatid cohesion defect
    description: Failure to couple cohesin to DNA replication reduces functional cohesion.
    causal_link_type: DIRECT
    hypothesis_groups:
    - replication_coupled_cohesion_model
    evidence:
    - reference: PMID:30303954
      reference_title: >-
        Interaction of the Warsaw breakage syndrome DNA helicase DDX11 with the
        replication fork-protection factor Timeless promotes sister chromatid
        cohesion.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        The DDX11-Timeless interaction is critical for sister chromatid cohesion
        in interphase and mitosis.
      explanation: Directly links the fork-protection interaction to cohesion.

- name: Sister chromatid cohesion defect
  biological_scale: CELLULAR
  description: >-
    Patient cells exhibit reduced sister chromatid cohesion. This is the
    consistent cytogenetic core of DDX11-related cohesinopathy and should not be
    conflated with the more variable induced-breakage phenotype.
  biological_processes:
  - preferred_term: sister chromatid cohesion
    modifier: DECREASED
    term:
      id: GO:0007062
      label: sister chromatid cohesion
  evidence:
  - reference: PMID:20137776
    reference_title: >-
      Warsaw breakage syndrome, a cohesinopathy associated with mutations in the
      XPD helicase family member DDX11/ChlR1.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The DDX11-deficient patient represents another cohesinopathy, besides
      Cornelia de Lange syndrome and Roberts syndrome, and shows that DDX11
      functions at the interface between DNA repair and sister chromatid cohesion.
    explanation: Establishes the patient-cell cohesion phenotype and DDX11 role.
  - reference: PMID:30469382
    reference_title: >-
      Molecular and Cellular Functions of the Warsaw Breakage Syndrome DNA
      Helicase DDX11.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While sister chromatid cohesion defects were observed in all the patients
      described so far, two of these novel WABS patients do not display
      drug-induced elevated chromosomal breakage.
    explanation: >-
      Supports treating cohesion failure as the consistent cellular signature
      while keeping induced breakage explicitly variable.
  downstream:
  - target: Premature chromatid separation and railroad chromosome morphology
    description: >-
      Insufficient cohesion permits premature separation of chromatids and
      centromeres, producing the characteristic railroad-track appearance.
    causal_link_type: DIRECT
    hypothesis_groups:
    - replication_coupled_cohesion_model
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
      reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        separation of the sister chromatids and centromeres during metaphase
        rather than in anaphase visible on C-banding techniques
      explanation: Defines the cytogenetic consequence of the cohesion defect.
  - target: Impaired embryonic proliferation and tissue development
    description: >-
      A developmental consequence is plausible from animal loss-of-function
      models, but the relevant human tissues and intervening mechanisms are
      unknown.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Tissue-specific replication stress, altered transcription, cell-cycle delay, or cell loss.
    hypothesis_groups:
    - replication_coupled_cohesion_model
    evidence:
    - reference: PMID:17611414
      reference_title: >-
        Loss of ChlR1 helicase in mouse causes lethality due to the accumulation
        of aneuploid cells generated by cohesion defects and placental malformation.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The mutant embryos were smaller in size, malformed and exhibited sparse
        cellularity in comparison to normal or heterozygous litter mates.
      explanation: >-
        Supports an in-vivo developmental consequence of complete Ddx11 loss,
        but not the organ-specific pathway in surviving humans.

- name: Premature chromatid separation and railroad chromosome morphology
  biological_scale: CELLULAR
  description: >-
    Premature chromatid separation, premature centromere division, centromeric
    heterochromatin repulsion, and railroad-track chromosomes are characteristic
    cytogenetic manifestations of the cohesion defect. Unlike induced breakage,
    this cohesion-related morphology is central to distinguishing WABS from
    Fanconi anemia.
  biological_processes:
  - preferred_term: chromosome segregation
    modifier: ABNORMAL
    term:
      id: GO:0007059
      label: chromosome segregation
  evidence:
  - reference: PMID:21490908
    reference_title: >-
      Diagnostic Overlap between Fanconi Anemia and the Cohesinopathies: Roberts
      Syndrome and Warsaw Breakage Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This complication may be avoided by scoring metaphase chromosomes-in
      addition to chromosomal breakage-for spontaneously occurring premature
      centromere division, which is characteristic for RBS and WABS, but not for
      FA.
    explanation: Supports both the cytogenetic signature and its diagnostic value.

- name: Variable cross-link-induced chromosome breakage
  biological_scale: CELLULAR
  description: >-
    Some patient lymphocytes show increased breaks and radial forms after
    diepoxybutane or mitomycin C exposure, reproducing part of the Fanconi-anemia
    cellular phenotype. Other molecularly confirmed individuals do not; this
    node is therefore explicitly variable and a normal breakage assay does not
    exclude the diagnosis.
  mechanism_confidence: ESTABLISHED
  evidence:
  - reference: PMID:20137776
    reference_title: >-
      Warsaw breakage syndrome, a cohesinopathy associated with mutations in the
      XPD helicase family member DDX11/ChlR1.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Defective DDX11 is associated with a unique cellular phenotype in which
      features of Fanconi anemia (drug-induced chromosomal breakage) and Roberts
      syndrome (sister chromatid cohesion defects) coexist.
    explanation: Documents the induced-breakage phenotype in the founding case.
  - reference: PMID:30216658
    reference_title: "Warsaw breakage syndrome: Further clinical and genetic delineation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that while the cardinal clinical features in WBS
      (microcephaly, growth retardation, and cochlear anomalies) are almost
      universally present, the breakage phenotype is highly variable and can be
      absent in some cases.
    explanation: Establishes non-penetrance of the breakage phenotype.

- name: rDNA chromatin and RNA polymerase I transcription defect
  biological_scale: CELLULAR
  description: >-
    In DDX11-depleted HeLa cells, active rDNA becomes more heterochromatic,
    recruitment of UBF and RNA polymerase I falls, and rRNA transcription is
    suppressed. WABS-derived mutant proteins show reduced rDNA-promoter binding
    and ATPase activity. The cell biology is experimentally supported, but its
    causal contribution to human WABS remains provisional.
  mechanism_confidence: PROVISIONAL
  biological_processes:
  - preferred_term: heterochromatin organization
    modifier: ABNORMAL
    term:
      id: GO:0070828
      label: heterochromatin organization
  - preferred_term: ribosome biogenesis
    modifier: DECREASED
    term:
      id: GO:0042254
      label: ribosome biogenesis
  evidence:
  - reference: PMID:26089203
    reference_title: >-
      The Warsaw breakage syndrome-related protein DDX11 is required for
      ribosomal RNA synthesis and embryonic development.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      R263Q and K897del, and a Fe-S deletion construct demonstrated significantly
      reduced binding abilities to rDNA promoters and lowered DNA-dependent
      ATPase activities compared with wild-type DDX11.
    explanation: Extends the rDNA defect from knockdown to two WABS-derived proteins.
  downstream:
  - target: Reduced cell proliferation
    description: Suppressed rRNA transcription reduces growth and proliferation in the cell model.
    causal_link_type: DIRECT
    hypothesis_groups:
    - rdna_ribosome_development_model
    evidence:
    - reference: PMID:26089203
      reference_title: >-
        The Warsaw breakage syndrome-related protein DDX11 is required for
        ribosomal RNA synthesis and embryonic development.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        DDX11 knockdown changed the epigenetic state of rDNA loci from
        euchromatic structures to more heterochromatic structures, reduced the
        activity of UBF, decreased the recruitment of UBF and RPA194 (a subunit
        of Pol I) to rDNA promoter, suppressed rRNA transcription and thereby
        inhibited growth and proliferation of HeLa cells.
      explanation: Directly links the rDNA transcription defect to impaired proliferation.

- name: Reduced cell proliferation
  biological_scale: CELLULAR
  description: >-
    DDX11 depletion reduces proliferation in cultured cells. A similar reduction
    in developmental cell production could contribute to growth restriction and
    microcephaly, but this extrapolation has not been demonstrated in relevant
    human embryonic tissues.
  mechanism_confidence: PROVISIONAL
  evidence:
  - reference: PMID:26089203
    reference_title: >-
      The Warsaw breakage syndrome-related protein DDX11 is required for
      ribosomal RNA synthesis and embryonic development.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      suppressed rRNA transcription and thereby inhibited growth and
      proliferation of HeLa cells.
    explanation: Directly supports reduced proliferation in the depletion model.
  downstream:
  - target: Impaired embryonic proliferation and tissue development
    description: >-
      Reduced cell production is proposed to impair embryonic growth and
      organogenesis, with tissue-specific intermediates unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Unknown tissue-specific effects of reduced ribosome output and cell-cycle progression.
    hypothesis_groups:
    - rdna_ribosome_development_model
    evidence:
    - reference: PMID:26089203
      reference_title: >-
        The Warsaw breakage syndrome-related protein DDX11 is required for
        ribosomal RNA synthesis and embryonic development.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Knockdown of the zebrafish ortholog of human DDX11 by morpholinos
        resulted in growth retardation and vertebral and craniofacial
        malformations in zebrafish, concomitant with the changes in histone
        epigenetic modifications at rDNA loci, the reduction of Pol I recruitment
        to the rDNA promoter and a significant decrease in nascent pre-RNA levels.
      explanation: >-
        Couples rDNA readouts to developmental abnormalities in vivo, while
        remaining indirect for human disease.

- name: Impaired embryonic proliferation and tissue development
  biological_scale: ORGANISM
  description: >-
    The cellular mechanisms are proposed to converge on impaired embryonic
    proliferation and organogenesis. Ddx11-null mice and DDX11-knockdown
    zebrafish establish developmental requirements for the gene, but neither
    model identifies the human tissue-specific intermediates that yield the
    clinical triad. This node and its phenotype edges are therefore explicitly
    hypothetical.
  mechanism_confidence: HYPOTHETICAL
  evidence:
  - reference: PMID:17611414
    reference_title: >-
      Loss of ChlR1 helicase in mouse causes lethality due to the accumulation of
      aneuploid cells generated by cohesion defects and placental malformation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The absence of Ddx11 resulted in embryonic lethality at E10.5.
    explanation: Shows that Ddx11 is required for mammalian embryonic development.
  - reference: PMID:26089203
    reference_title: >-
      The Warsaw breakage syndrome-related protein DDX11 is required for
      ribosomal RNA synthesis and embryonic development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These growth disruptions in zebrafish in response to DDX11 reduction
      showed similarities to the clinically described developmental
      abnormalities found in WABS patients for the first time in any vertebrate.
    explanation: Shows partial developmental phenocopy after DDX11 reduction.
  downstream:
  - target: Intrauterine growth retardation
    description: >-
      Prenatal growth failure is universal in reported individuals, but the
      causal tissue and cellular bottleneck are not established.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Postnatal growth retardation
    description: >-
      Persistent growth deficiency may reflect reduced cell production and
      nutritional factors; their relative contributions are unknown.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Congenital microcephaly
    description: >-
      Reduced prenatal brain growth is plausibly downstream of impaired
      development, but neural progenitor-specific causality has not been tested.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Abnormal brain morphology
    description: >-
      Structural brain anomalies occur in a minority of affected individuals,
      but their lineage-specific developmental mechanism remains unknown.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Abnormal cortical gyration
    description: >-
      Poor sulcation, delayed gyration, and focal lissencephaly implicate cortical
      development through untested neural-progenitor intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Hypoplasia of the corpus callosum
    description: >-
      Callosal hypoplasia is plausibly developmental, but no DDX11-dependent
      axon-guidance or commissural-neuron mechanism has been demonstrated.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Cerebellar vermis hypoplasia
    description: >-
      Vermian hypoplasia is reported clinically, but the affected progenitor
      population and causal molecular branch are unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Congenital sensorineural hearing impairment
    description: >-
      Hearing impairment reflects abnormal cochlear development; the relevant
      embryonic cell population and molecular route from DDX11 remain unknown.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Cochlear malformation
    description: The tissue-selective basis of cochlear hypoplasia is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Intellectual disability
    description: >-
      Cognitive impairment is associated with congenital brain growth and
      hearing-language effects, but its direct cellular mechanism is unknown.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Delayed speech and language development
    description: >-
      Severe hearing impairment is a known contributor to speech delay, while
      intellectual disability may additionally limit receptive language.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Congenital sensorineural hearing impairment and limited auditory input.
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Global developmental delay
    description: >-
      Mild developmental delay is variably present; affected developmental
      programs have not been defined.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Abnormal facial shape
    description: Craniofacial patterning is affected, but the cellular route is unknown.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Multiple skeletal anomalies
    description: Limb and skeletal development can be affected through unknown intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Abnormal heart morphology
    description: Congenital cardiac anomalies are variably present; their mechanism is unknown.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Abnormality of skin pigmentation
    description: Pigmentary abnormalities are variably present; the responsible cell lineage is unknown.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model
  - target: Abnormality of the genitourinary system
    description: Genitourinary malformations occur in some individuals through unknown developmental intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - replication_coupled_cohesion_model
    - rdna_ribosome_development_model

phenotypes:
- name: Intrauterine growth retardation
  category: Growth
  diagnostic: true
  frequency: OBLIGATE
  description: >-
    Prenatal growth restriction is a cardinal feature and was reported in all 26
    individuals summarized in the 2025 GeneReviews update.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All 26 reported individuals to date had intrauterine growth deficiency
      with birth weight and height below the third centile.
    explanation: Provides the reported frequency and severity of prenatal growth deficiency.
- name: Postnatal growth retardation
  category: Growth
  diagnostic: true
  frequency: OBLIGATE
  description: >-
    Growth deficiency persists after birth, although nutritional support can
    improve weight in some individuals.
  phenotype_term:
    preferred_term: Postnatal growth retardation
    term:
      id: HP:0008897
      label: Postnatal growth retardation
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Postnatal growth deficiency was also reported in all individuals; two
      individuals had weights between the 50th and 75th percentile later in
      childhood, after they were started on gastrostomy tube feedings
    explanation: Documents persistent postnatal deficiency and possible nutritional response.
- name: Congenital microcephaly
  category: Neurologic
  diagnostic: true
  frequency: OBLIGATE
  description: >-
    Severe congenital microcephaly is part of the defining triad and begins
    prenatally; reported measurements range from 3.3 to 10 standard deviations
    below the mean.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
    severity: SEVERE
    onset:
      onset_category: ANTENATAL
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      has a prenatal onset and is reported in all affected individuals.
      Congenital microcephaly can range from 3.3 to 10 standard deviations (SD)
      below the mean for age and sex.
    explanation: Establishes prenatal onset and reported universality.
- name: Abnormal brain morphology
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Structural brain anomalies were reported in 8 of the 26 individuals
    summarized by GeneReviews (30.8%). Findings included abnormal cortical
    sulcation or gyration, focal lissencephaly, corpus callosum hypoplasia, and
    cerebellar vermis hypoplasia. This frequency applies to any structural brain
    anomaly collectively, not to each component finding.
  phenotype_term:
    preferred_term: Abnormal brain morphology
    term:
      id: HP:0012443
      label: Abnormal brain morphology
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eight individuals presented with brain anomalies including focal poor
      sulcation pattern, delayed gyration, focal lissencephaly, corpus callosum
      hypoplasia, and cerebellar vermis hypoplasia
    explanation: Supplies the numerator and the reported structural brain spectrum.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      related cohesinopathy is rare, with 26 individuals reported to date
    explanation: >-
      Supplies the GeneReviews cohort denominator; 8 of 26 is 30.8% and maps to
      the FREQUENT band.
- name: Abnormal cortical gyration
  category: Neurologic
  description: >-
    The reported cortical-development spectrum includes focal poor sulcation,
    delayed gyration, and focal lissencephaly. GeneReviews does not provide a
    separate denominator for this component, so no component frequency is assigned.
  phenotype_term:
    preferred_term: Abnormal cortical gyration
    term:
      id: HP:0002536
      label: Abnormal cortical gyration
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eight individuals presented with brain anomalies including focal poor
      sulcation pattern, delayed gyration, focal lissencephaly, corpus callosum
      hypoplasia, and cerebellar vermis hypoplasia
    explanation: Directly identifies cortical gyration and sulcation abnormalities.
- name: Hypoplasia of the corpus callosum
  category: Neurologic
  description: >-
    Corpus callosum hypoplasia is part of the reported structural brain spectrum;
    its individual frequency was not reported separately from the 8-person group.
  phenotype_term:
    preferred_term: Hypoplasia of the corpus callosum
    term:
      id: HP:0002079
      label: Hypoplasia of the corpus callosum
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eight individuals presented with brain anomalies including focal poor
      sulcation pattern, delayed gyration, focal lissencephaly, corpus callosum
      hypoplasia, and cerebellar vermis hypoplasia
    explanation: Directly includes corpus callosum hypoplasia in the reported spectrum.
- name: Cerebellar vermis hypoplasia
  category: Neurologic
  description: >-
    Cerebellar vermis hypoplasia is part of the reported structural brain
    spectrum; its individual frequency was not reported separately from the
    8-person group.
  phenotype_term:
    preferred_term: Cerebellar vermis hypoplasia
    term:
      id: HP:0001320
      label: Cerebellar vermis hypoplasia
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eight individuals presented with brain anomalies including focal poor
      sulcation pattern, delayed gyration, focal lissencephaly, corpus callosum
      hypoplasia, and cerebellar vermis hypoplasia
    explanation: Directly includes cerebellar vermis hypoplasia in the reported spectrum.
- name: Congenital sensorineural hearing impairment
  category: Otolaryngologic
  diagnostic: true
  frequency: VERY_FREQUENT
  description: >-
    Congenital sensorineural hearing impairment is usually severe and is closely
    associated with cochlear and cochlear-nerve hypoplasia.
  phenotype_term:
    preferred_term: Congenital sensorineural hearing impairment
    term:
      id: HP:0008527
      label: Congenital sensorineural hearing impairment
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DDX11-related cohesinopathy is characterized by the clinical triad of
      severe congenital microcephaly, growth restriction, and sensorineural
      hearing loss due to cochlear hypoplasia.
    explanation: Defines hearing loss as one arm of the core clinical triad.
- name: Cochlear malformation
  category: Otolaryngologic
  diagnostic: true
  frequency: VERY_FREQUENT
  description: >-
    Bilateral cochlear hypoplasia or another cochlear anomaly is the structural
    substrate for the characteristic congenital hearing impairment.
  phenotype_term:
    preferred_term: Cochlear malformation
    term:
      id: HP:0008554
      label: Cochlear malformation
  evidence:
  - reference: PMID:30216658
    reference_title: "Warsaw breakage syndrome: Further clinical and genetic delineation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although all the reported patients had cochlear hypoplasia, one patient
      also had posterior labyrinthine anomaly.
    explanation: Documents high penetrance and variable inner-ear morphology.
- name: Intellectual disability
  category: Neurodevelopmental
  description: >-
    Intellectual disability is usually mild to moderate and stable, but severity
    varies and some molecularly confirmed individuals have no intellectual
    disability.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
    clinical_course: STABLE
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Intellectual disability is typically in the mild-to-moderate range.
    explanation: Describes the usual severity.
  - reference: PMID:30924321
    reference_title: >-
      Two further patients with Warsaw breakage syndrome. Is a mild phenotype
      possible?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings further extend the clinical and molecular knowledge about
      the WABS showing a possible mild phenotype without major malformations or
      intellectual disability.
    explanation: Establishes that intellectual disability is not obligate.
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      <b>Intellectual disability and developmental delay</b> range from mild to
      moderate and tend to be stable.
    explanation: Directly supports the typical stable clinical course.
- name: Delayed speech and language development
  category: Neurodevelopmental
  description: >-
    Severe speech delay is common and expressive language is especially affected
    by congenital hearing impairment; receptive language can also be limited by
    intellectual disability.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Severe speech delay is common.
    explanation: Directly supports speech delay as a common feature.
- name: Global developmental delay
  category: Neurodevelopmental
  description: >-
    Developmental delay is generally mild to moderate and stable. Gross and fine
    motor milestones are often attained on time, so this phenotype should not be
    interpreted as uniformly severe global delay.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
    clinical_course: STABLE
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      range from mild to moderate and tend to be stable. Gross and fine motor
      milestones are usually attained at the usual time although a few
      individuals have mild delays.
    explanation: Directly supports developmental delay while calibrating its typical course.
- name: Abnormal facial shape
  category: Craniofacial
  description: Facial dysmorphism is recurrent but variable.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:28960803
    reference_title: "Clinical Report: Warsaw Breakage Syndrome with small radii and fibulae."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The sisters reported here display the distinguishing clinical features of
      WABS: pre- and post-natal growth restriction, microcephaly, intellectual
      disability, sensorineural hearing loss with cochlear abnormalities, and
      facial dysmorphic features.
    explanation: Documents facial dysmorphism in two molecularly confirmed siblings.
- name: Multiple skeletal anomalies
  category: Musculoskeletal
  frequency: FREQUENT
  description: >-
    Skeletal findings include short or proximally inserted thumbs, shortened
    first metacarpals, small radii or fibulae, syndactyly, clinodactyly, and
    overlapping toes; severity varies.
  phenotype_term:
    preferred_term: Multiple skeletal anomalies
    term:
      id: HP:0005775
      label: Multiple skeletal anomalies
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      are commonly seen (16/23 individuals), including proximal insertion of
      thumbs, shortened first metacarpals, small radii, syndactyly, and short
      thumbs.
    explanation: Quantifies skeletal involvement and provides representative findings.
  - reference: PMID:28960803
    reference_title: "Clinical Report: Warsaw Breakage Syndrome with small radii and fibulae."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In addition, our cases had early menarche at 8 and 10 years of age,
      bilateral small thumbs, and the younger, more severely affected sister had
      small fibulae.
    explanation: Extends the limb phenotype to small thumbs and fibulae.
- name: Abnormal heart morphology
  category: Cardiovascular
  frequency: FREQUENT
  description: >-
    Congenital cardiovascular anomalies include patent ductus arteriosus, atrial
    or ventricular septal defects, and tetralogy of Fallot.
  phenotype_term:
    preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      are reported in 33% (7/21 individuals). These include patent ductus
      arteriosus (1), small atrial septal defect with large patent ductus
      arteriosus (1), ventricular septal defect (4), and tetralogy of Fallot (1).
    explanation: Provides the available cohort frequency.
- name: Abnormality of skin pigmentation
  category: Dermatologic
  description: >-
    Reported pigmentary and vascular-pattern findings include café-au-lait
    macules, hypo- or hyperpigmentation, cutis marmorata, and livedo reticularis
    with telangiectasia.
  phenotype_term:
    preferred_term: Abnormality of skin pigmentation
    term:
      id: HP:0001000
      label: Abnormality of skin pigmentation
  evidence:
  - reference: PMID:25701697
    reference_title: >-
      Warsaw Breakage Syndrome--A further report, emphasising cutaneous findings.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In our case the patient exhibited a chronic rash of livedo reticularis with
      telangiectasia on her legs. Abnormally pigmented lesions and cutis mamorata
      were reported in the original WABS case.
    explanation: Documents the spectrum and recurrence of cutaneous pigmentation findings.
- name: Abnormality of the genitourinary system
  category: Genitourinary
  description: >-
    Hypoplastic scrotum, cryptorchidism, hypospadias, and multicystic kidneys
    have been reported in individual cases.
  phenotype_term:
    preferred_term: Abnormality of the genitourinary system
    term:
      id: HP:0000119
      label: Abnormality of the genitourinary system
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abnormal skin pigmentation and genitourinary malformations have also been
      reported.
    explanation: Supports genitourinary malformations as part of the reported spectrum.
- name: Seizure
  category: Neurologic
  description: >-
    Epilepsy is not part of the defining triad but has been reported in multiple
    children. Phenotypes can include focal seizures, epileptic spasms, and drug
    resistance; ascertainment and denominator data remain limited.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:41853675
    reference_title: >-
      A pediatric patient with Warsaw breakage syndrome presenting with epilepsy:
      a case report and literature review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A literature review identified a total of 7 previously reported children
      with WABS complicated by epilepsy, and we collected and summarized their
      clinical and genetic information.
    explanation: Documents recurrence of epilepsy beyond a single patient.

differential_diagnoses:
- name: Fanconi anemia
  description: >-
    Fanconi anemia overlaps through prenatal growth deficiency, microcephaly,
    limb and pigmentary anomalies, and cross-linker-induced chromosome breakage.
    Progressive bone-marrow failure and pancytopenia favor Fanconi anemia;
    congenital sensorineural hearing impairment with cochlear hypoplasia and
    spontaneous premature centromere division favor DDX11-related cohesinopathy.
  distinguishing_features:
  - Progressive bone-marrow failure with pancytopenia is characteristic of Fanconi anemia.
  - Hearing loss in Fanconi anemia is usually conductive rather than the congenital sensorineural loss of WABS.
  - Premature centromere division is characteristic of WABS and Roberts syndrome but not Fanconi anemia.
  disease_term:
    preferred_term: Fanconi anemia
    term:
      id: MONDO:0019391
      label: Fanconi anemia
  evidence:
  - reference: PMID:21490908
    reference_title: >-
      Diagnostic Overlap between Fanconi Anemia and the Cohesinopathies: Roberts
      Syndrome and Warsaw Breakage Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This complication may be avoided by scoring metaphase chromosomes-in
      addition to chromosomal breakage-for spontaneously occurring premature
      centromere division, which is characteristic for RBS and WABS, but not for
      FA.
    explanation: Gives the key cytogenetic discriminator from Fanconi anemia.
- name: Roberts-SC phocomelia syndrome
  description: >-
    ESCO2-related Roberts syndrome is another autosomal recessive cohesinopathy
    with prenatal growth restriction, limb anomalies, and premature centromere
    separation. Bilateral symmetric tetraphocomelia or hypomelia, contractures,
    ear malformations, and corneal opacities favor Roberts syndrome; congenital
    sensorineural hearing impairment is not characteristic.
  distinguishing_features:
  - Roberts syndrome is caused by biallelic ESCO2 variants rather than DDX11 variants.
  - Severe symmetric limb reduction defects and flexion contractures favor Roberts syndrome.
  - Sensorineural hearing impairment with cochlear hypoplasia favors WABS.
  disease_term:
    preferred_term: Roberts-SC phocomelia syndrome
    term:
      id: MONDO:0100253
      label: Roberts-SC phocomelia syndrome
  evidence:
  - reference: PMID:20137776
    reference_title: >-
      Warsaw breakage syndrome, a cohesinopathy associated with mutations in the
      XPD helicase family member DDX11/ChlR1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Defective DDX11 is associated with a unique cellular phenotype in which
      features of Fanconi anemia (drug-induced chromosomal breakage) and Roberts
      syndrome (sister chromatid cohesion defects) coexist.
    explanation: Establishes the cohesion-based overlap with Roberts syndrome.
- name: Nijmegen breakage syndrome
  description: >-
    Nijmegen breakage syndrome overlaps through microcephaly, growth deficiency,
    and chromosome instability. Progressive microcephaly, immunodeficiency,
    characteristic chromosome 7/14 rearrangements, premature ovarian failure,
    and lymphoma risk favor Nijmegen breakage syndrome; sensorineural hearing
    impairment is not typical.
  distinguishing_features:
  - Immunodeficiency and marked lymphoma predisposition favor Nijmegen breakage syndrome.
  - Chromosome 7 and 14 inversions or translocations favor Nijmegen breakage syndrome.
  - Congenital cochlear hypoplasia and sensorineural hearing impairment favor WABS.
  disease_term:
    preferred_term: Nijmegen breakage syndrome
    term:
      id: MONDO:0009623
      label: Nijmegen breakage syndrome
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chromosome instability (inversions &#x00026; translocations involving
      chromosomes 7 &#x00026; 14)
    explanation: Provides a specific cytogenetic discriminator for Nijmegen breakage syndrome.
- name: Microcephalic osteodysplastic primordial dwarfism type II
  description: >-
    PCNT-related microcephalic osteodysplastic primordial dwarfism type II
    overlaps through severe microcephaly and pre- and postnatal growth
    deficiency. More extreme short stature, central-nervous-system vascular
    anomalies, insulin resistance, and absence of cochlear hypoplasia favor the
    primordial-dwarfism diagnosis.
  distinguishing_features:
  - Growth deficiency and short stature are generally more severe in MOPD II.
  - CNS vascular anomalies and insulin resistance favor MOPD II.
  - Cochlear hypoplasia and the WABS cohesion phenotype are absent from MOPD II.
  disease_term:
    preferred_term: microcephalic osteodysplastic primordial dwarfism type II
    term:
      id: MONDO:0008872
      label: microcephalic osteodysplastic primordial dwarfism type II
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/books/NBK541972/
    reference_title: "DDX11-Related Cohesinopathy - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Growth deficiency is more severe; extremely short stature
    explanation: Provides a principal clinical discriminator for MOPD II.

diagnosis:
- name: Clinical recognition of the core triad
  description: >-
    Suspect DDX11-related cohesinopathy in an individual with severe congenital
    microcephaly, prenatal and postnatal growth restriction, and congenital
    sensorineural hearing impairment caused by cochlear abnormalities. Skeletal,
    cardiac, pigmentary, genitourinary, and cytogenetic findings can support the
    suspicion, but no consensus clinical diagnostic criteria exist.
  diagnosis_term:
    preferred_term: Clinical Evaluation
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DDX11-related cohesinopathy is characterized by the clinical triad of
      severe congenital microcephaly, growth restriction, and sensorineural
      hearing loss due to cochlear hypoplasia.
    explanation: Defines the clinical pattern that should trigger testing.
- name: DDX11 molecular genetic testing
  description: >-
    The diagnosis is established by identifying biallelic pathogenic or likely
    pathogenic DDX11 variants. Depending on presentation, testing may use DDX11
    sequencing, an appropriate multigene panel, exome sequencing, or genome
    sequencing. A negative or single-variant sequence result may warrant
    deletion/duplication analysis; highly homologous DDX11 pseudogenes complicate
    assay design and interpretation.
  diagnosis_term:
    preferred_term: Genetic Testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of DDX11-related cohesinopathy is established in a proband
      with biallelic pathogenic variants in DDX11 identified by molecular genetic
      testing.
    explanation: Directly states the molecular diagnostic criterion.
- name: Supportive cytogenetic analysis
  description: >-
    C-banded metaphase analysis can show premature chromatid separation,
    premature centromere division, and railroad chromosomes. DEB- or MMC-treated
    lymphocytes can show increased breaks and radial forms, but this induced
    breakage is variable and can be absent; a normal breakage assay therefore
    cannot exclude WABS, and molecular confirmation remains necessary.
  diagnosis_term:
    preferred_term: Karyotyping
    term:
      id: NCIT:C16768
      label: Karyotyping
  evidence:
  - reference: PMID:21490908
    reference_title: >-
      Diagnostic Overlap between Fanconi Anemia and the Cohesinopathies: Roberts
      Syndrome and Warsaw Breakage Syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This complication may be avoided by scoring metaphase chromosomes-in
      addition to chromosomal breakage-for spontaneously occurring premature
      centromere division, which is characteristic for RBS and WABS, but not for
      FA.
    explanation: Supports scoring cohesion morphology during the cytogenetic differential.
  - reference: PMID:30216658
    reference_title: "Warsaw breakage syndrome: Further clinical and genetic delineation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We conclude that while the cardinal clinical features in WBS
      (microcephaly, growth retardation, and cochlear anomalies) are almost
      universally present, the breakage phenotype is highly variable and can be
      absent in some cases.
    explanation: Establishes that absence of induced breakage does not exclude WABS.

genetic:
- name: DDX11
  association: Biallelic pathogenic variants are causative
  gene_term:
    preferred_term: DDX11
    term:
      id: hgnc:2736
      label: DDX11
  evidence:
  - reference: PMID:20137776
    reference_title: >-
      Warsaw breakage syndrome, a cohesinopathy associated with mutations in the
      XPD helicase family member DDX11/ChlR1.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report a human individual with biallelic mutations in DDX11.
    explanation: The founding report identifies biallelic DDX11 variants in WABS.
  - reference: PMID:23033317
    reference_title: >-
      Identification and biochemical characterization of a novel mutation in
      DDX11 causing Warsaw breakage syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Biochemical studies of purified recombinant DDX11 indicated that the
      p.R263Q mutation impaired DDX11 helicase activity by perturbing its DNA
      binding and DNA-dependent ATP hydrolysis.
    explanation: Provides functional evidence for a disease-associated allele.
  - reference: CGGV:assertion_99d606e6-7d37-4502-bf44-bbf2db469459-2025-02-21T170000.000Z
    reference_title: DDX11 / Warsaw breakage syndrome (Definitive)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: DDX11 | HGNC:2736 | Warsaw breakage syndrome | MONDO:0013252 | AR | Definitive
    explanation: >-
      ClinGen classifies the autosomal recessive DDX11-WABS gene-disease
      relationship as definitive.

clinical_trials: []
datasets: []
biochemical: []
environmental: []

treatments:
- name: Nutritional support for poor weight gain
  action_category: THERAPEUTIC
  description: >-
    Optimize nutrition for poor weight gain; supplementary formula and
    gastrostomy feeding can be used when needed. This is supportive care and
    does not correct the underlying DDX11 defect.
  treatment_term:
    preferred_term: Nutritional Support
    term:
      id: NCIT:C15433
      label: Nutritional Support
  target_phenotypes:
  - preferred_term: Postnatal growth retardation
    term:
      id: HP:0008897
      label: Postnatal growth retardation
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Supplementary formula and/or gastrostomy tube as needed to optimize
      nutrition.
    explanation: Provides the GeneReviews nutrition recommendation.
- name: Hearing habilitation and communication support
  action_category: THERAPEUTIC
  description: >-
    Management depends on residual cochlear and cochlear-nerve anatomy and can
    include hearing aids, cochlear implantation when a cochlear nerve is present,
    or an auditory brainstem implant for profound loss with absent or
    nonfunctioning cochlea or auditory nerve. Communication support should begin
    promptly and may include sign language, auditory therapy, speech-language
    therapy, and hearing-focused education.
  treatment_term:
    preferred_term: Rehabilitation
    term:
      id: NCIT:C15315
      label: Rehabilitation
  target_phenotypes:
  - preferred_term: Congenital sensorineural hearing impairment
    term:
      id: HP:0008527
      label: Congenital sensorineural hearing impairment
  - preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatments for hearing loss include hearing aids; cochlear implantation;
      auditory brain stem implant for individuals with profound hearing loss due
      to missing or nonfunctioning cochlea or auditory nerve; establishing a
      system of communication and hearing habilitation that may include sign
      language, auditory therapy, and speech therapy; and educational programs
      designed for individuals with hearing impairment.
    explanation: Directly supports the anatomy-dependent hearing and communication options.
- name: Early developmental and educational intervention
  action_category: THERAPEUTIC
  description: >-
    Provide early intervention and individualized educational support, with
    physical, occupational, and speech-language therapy according to need.
  treatment_term:
    preferred_term: Early Intervention
    term:
      id: NCIT:C159524
      label: Early Intervention
  target_phenotypes:
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  - preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early intervention and educational support; physical, occupational, and
      speech therapies
    explanation: States the recommended developmental supports.
- name: Organ-specific specialist management
  action_category: THERAPEUTIC
  description: >-
    Treat congenital cardiac anomalies with cardiology, limb anomalies with
    orthopedics and occupational therapy, and genitourinary anomalies with
    nephrology or urology. Management is individualized and supportive.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  - preferred_term: Multiple skeletal anomalies
    term:
      id: HP:0005775
      label: Multiple skeletal anomalies
  - preferred_term: Abnormality of the genitourinary system
    term:
      id: HP:0000119
      label: Abnormality of the genitourinary system
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      treatment of cardiac anomalies per cardiologist; treatment of limb
      anomalies per orthopedist with occupational therapy as needed; treatment
      of genitourinary anomalies per nephrologist and/or urologist.
    explanation: Directly supports specialist-directed supportive management.
- name: Growth, development, and behavior surveillance
  action_category: MONITORING
  description: >-
    Measure height, weight, head circumference, and body mass index and review
    speech development and educational needs at every visit. Assess for ADHD or
    other behavioral concerns when clinically indicated. There is no consensus
    for tumor screening because malignancy risk remains unproven.
  treatment_term:
    preferred_term: Clinical Evaluation
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Monitor growth, speech development, and educational needs with each visit;
      behavioral assessment for ADHD as needed; there is no consensus regarding
      tumor screening.
    explanation: States the longitudinal surveillance recommendations and tumor-screening uncertainty.
- name: Genetic counseling and reproductive testing
  action_category: COUNSELING_INFORMATIONAL
  description: >-
    Counsel families about autosomal recessive inheritance and the 25% recurrence
    risk when both parents carry a pathogenic variant. Once familial DDX11
    variants are known, offer carrier testing to at-risk relatives and discuss
    prenatal and preimplantation genetic testing.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Once the DDX11 pathogenic variants have been identified in an affected
      family member, carrier testing for at-risk relatives and
      prenatal/preimplantation genetic testing are possible.
    explanation: Supports cascade and reproductive testing after familial variant identification.

experimental_models:
- name: Patient-derived lymphocyte and lymphoblastoid cell models
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: >-
    Primary T lymphocytes and Epstein-Barr-virus-immortalized B-lymphoblastoid
    lines from molecularly confirmed affected individuals
  description: >-
    Patient cells reveal the disease-proximal cytogenetic phenotype: sister
    chromatid cohesion defects, premature centromere division, and in some
    individuals cross-linker-induced chromosome breakage. WABS-derived cells also
    show reduced replication-fork speed and dependence on residual ESCO2-mediated
    cohesion. The platform is strong for cell-autonomous genome-maintenance
    mechanisms but cannot reproduce organogenesis or neural and cochlear tissue
    selectivity.
  evidence:
  - reference: PMID:20137776
    reference_title: >-
      Warsaw breakage syndrome, a cohesinopathy associated with mutations in the
      XPD helicase family member DDX11/ChlR1.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Defective DDX11 is associated with a unique cellular phenotype in which
      features of Fanconi anemia (drug-induced chromosomal breakage) and Roberts
      syndrome (sister chromatid cohesion defects) coexist.
    explanation: Establishes the core patient-cell model readouts.
  - reference: PMID:31935221
    reference_title: >-
      Non-redundant roles in sister chromatid cohesion of the DNA helicase DDX11
      and the SMC3 acetyl transferases ESCO1 and ESCO2.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We found that WABS-derived cells predominantly rely on ESCO2, not ESCO1,
      for residual SCC, growth and survival.
    explanation: Supports ESCO2 dependence as an experimentally tractable patient-cell phenotype.
- name: DDX11-depleted and complementation human cell-line models
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: Homo sapiens
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: >-
    HeLa and other human cell lines with DDX11 depletion, mutant complementation,
    or Timeless-interaction perturbation
  description: >-
    Engineered human cells resolve two experimentally separable functions:
    DDX11-Timeless-dependent recruitment of cohesin at replication forks, and
    nucleolar DDX11-dependent maintenance of active rDNA and RNA polymerase I
    transcription. These systems establish cellular mechanisms but are not
    patient-derived developmental tissue models.
  evidence:
  - reference: PMID:30303954
    reference_title: >-
      Interaction of the Warsaw breakage syndrome DNA helicase DDX11 with the
      replication fork-protection factor Timeless promotes sister chromatid
      cohesion.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We demonstrated that DDX11 interacts with Timeless, a component of the
      replication fork-protection complex, through a conserved peptide motif.
    explanation: Establishes the engineered-cell fork/cohesion mechanism.
  - reference: PMID:26089203
    reference_title: >-
      The Warsaw breakage syndrome-related protein DDX11 is required for
      ribosomal RNA synthesis and embryonic development.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      DDX11 knockdown changed the epigenetic state of rDNA loci from euchromatic
      structures to more heterochromatic structures, reduced the activity of UBF,
      decreased the recruitment of UBF and RPA194 (a subunit of Pol I) to rDNA
      promoter, suppressed rRNA transcription and thereby inhibited growth and
      proliferation of HeLa cells.
    explanation: Establishes the engineered-cell rDNA and proliferation phenotype.

animal_models:
- species: Danio rerio
  genotype: Morpholino knockdown of the zebrafish DDX11 ortholog
  description: >-
    DDX11 knockdown produces growth retardation and vertebral and craniofacial
    malformations while reducing Pol I recruitment and nascent pre-rRNA. This is
    the only model linking rDNA readouts to a partial WABS-like developmental
    phenotype, but morpholino knockdown is not a stable allele and the model did
    not reproduce or assay the human cochlear and neurocognitive phenotype.
  genes:
  - preferred_term: DDX11
    term:
      id: hgnc:2736
      label: DDX11
  evidence:
  - reference: PMID:26089203
    reference_title: >-
      The Warsaw breakage syndrome-related protein DDX11 is required for
      ribosomal RNA synthesis and embryonic development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Knockdown of the zebrafish ortholog of human DDX11 by morpholinos resulted
      in growth retardation and vertebral and craniofacial malformations in
      zebrafish, concomitant with the changes in histone epigenetic modifications
      at rDNA loci, the reduction of Pol I recruitment to the rDNA promoter and a
      significant decrease in nascent pre-RNA levels.
    explanation: Defines both developmental and molecular readouts of the zebrafish model.
- species: Mus musculus
  genotype: Homozygous Ddx11-null mouse
  description: >-
    Complete Ddx11 loss causes embryonic lethality around E10.5, small malformed
    embryos, placental failure, G2/M delay, chromosome missegregation, reduced
    cohesion, and aneuploidy. It establishes an essential mammalian developmental
    role but is a severity mismatch for surviving humans with hypomorphic or
    partially functional biallelic alleles.
  genes:
  - preferred_term: DDX11
    term:
      id: hgnc:2736
      label: DDX11
  evidence:
  - reference: PMID:17611414
    reference_title: >-
      Loss of ChlR1 helicase in mouse causes lethality due to the accumulation of
      aneuploid cells generated by cohesion defects and placental malformation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The absence of Ddx11 resulted in embryonic lethality at E10.5.
    explanation: Establishes the survival phenotype of complete murine loss.
  - reference: PMID:17611414
    reference_title: >-
      Loss of ChlR1 helicase in mouse causes lethality due to the accumulation of
      aneuploid cells generated by cohesion defects and placental malformation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Detailed analysis of cells isolated from Ddx11-/- embryos revealed a G2/M
      cell cycle delay, an increased frequency of chromosome missegregation,
      decreased chromosome cohesion, and increased aneuploidy.
    explanation: Defines the cohesion and genome-segregation readouts in the mouse model.

discussions:
- discussion_id: organ_specific_developmental_bridge
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Which DDX11-dependent cellular defect causes each organ-specific human
    manifestation: replication-fork slowing, failed cohesion, altered chromatin
    and transcription, impaired rRNA synthesis, or a combination?
  attaches_to:
  - pathophysiology#Slowed replication forks and defective replication-coupled cohesin loading
  - pathophysiology#rDNA chromatin and RNA polymerase I transcription defect
  - pathophysiology#Impaired embryonic proliferation and tissue development
  rationale: >-
    The fork/cohesion and rDNA branches are experimentally reproducible, but no
    disease-relevant human neural, cochlear, cardiac, or embryonic model connects
    either branch to the defining congenital phenotype. Resolving this bridge is
    necessary before any organ-specific mechanism or disease-modifying target can
    be considered established.
  evidence:
  - reference: PMID:26089203
    reference_title: >-
      The Warsaw breakage syndrome-related protein DDX11 is required for
      ribosomal RNA synthesis and embryonic development.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These growth disruptions in zebrafish in response to DDX11 reduction
      showed similarities to the clinically described developmental
      abnormalities found in WABS patients for the first time in any vertebrate.
    explanation: >-
      Demonstrates partial model convergence but not the human organ-specific
      causal bridge, which is why the item remains open.
- discussion_id: complete_loss_model_mismatch
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Can a stable allelic animal or human developmental model reproduce the
    survivable, tissue-selective phenotype of human WABS rather than the early
    lethality of complete Ddx11 loss or the limitations of morpholino knockdown?
  attaches_to:
  - pathophysiology#Pathogenic DDX11 helicase dysfunction
  - pathophysiology#Impaired embryonic proliferation and tissue development
  rationale: >-
    The null mouse demonstrates gene necessity but dies before relevant organ
    phenotypes can be assessed, while the zebrafish model is transient and only
    partially phenocopies WABS. Patient-variant knock-in models, ideally with
    lineage-resolved neural and inner-ear readouts, are needed.
  evidence:
  - reference: PMID:17611414
    reference_title: >-
      Loss of ChlR1 helicase in mouse causes lethality due to the accumulation of
      aneuploid cells generated by cohesion defects and placental malformation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The absence of Ddx11 resulted in embryonic lethality at E10.5.
    explanation: Defines the central severity mismatch of the available mouse model.
- discussion_id: natural_history_and_malignancy_risk
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What are the adult natural history, malignancy risk, treatment toxicities,
    and evidence-based surveillance needs of people with biallelic DDX11 disease
    and of heterozygous carriers?
  attaches_to:
  - phenotypes#Seizure
  rationale: >-
    Published cohorts are small, most affected individuals are children, and no
    consensus tumor-screening protocol exists. A longitudinal registry is needed
    to distinguish true late complications from isolated observations and to
    assess whether DNA-damaging therapies require special precautions.
  evidence:
  - reference: PMID:31169992
    reference_title: DDX11-Related Cohesinopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Surveillance: Monitor growth, speech development, and educational needs
      with each visit; behavioral assessment for ADHD as needed; there is no
      consensus regarding tumor screening.
    explanation: Documents the current surveillance scope and tumor-screening uncertainty.
- discussion_id: serf1b_snca_neurotoxicity_model
  kind: EMERGING_HYPOTHESIS
  status: UNDER_DISCUSSION
  prompt: >-
    Does DDX11 deficiency reproducibly activate a SERF1B-SNCA aggregation pathway
    that contributes to impaired neuronal migration and neurodevelopment in WABS?
  attaches_to:
  - phenotypes#Congenital microcephaly
  - phenotypes#Intellectual disability
  - phenotypes#Seizure
  rationale: >-
    A 2026 study reported this pathway using variants from one family, a
    transfected neural-cell model, RNA sequencing, and validation in fetal
    tissue. Independent patient-derived neural models, protein-aggregation
    measurements, genetic rescue, and replication across alleles are needed
    before it can enter the core disease graph.
  evidence:
  - reference: PMID:42107920
    reference_title: >-
      Genetic characterization of DDX11 variants identified in a Chinese family
      with Warsaw breakage syndrome.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      RNA-seq revealed marked upregulation of SERF1B, which was validated in
      fetal tissue. Mechanistically, SERF1B overexpression may accelerate SNCA
      protein aggregation and exacerbate neurotoxicity.
    explanation: States the newly proposed molecular pathway and its limited validation.

notes: >-
  Evidence calibration: sister chromatid cohesion failure is the consistent
  cellular signature, while induced chromosome breakage is explicitly variable
  and cannot be required for diagnosis. Replication-fork and cohesion mechanisms
  are supported by patient cells and independent perturbation studies. The rDNA
  and ribosome-biogenesis branch is experimentally supported in HeLa cells and a
  zebrafish knockdown model, but its contribution to human manifestations remains
  provisional. All links from cellular dysfunction to individual congenital
  phenotypes are marked indirect because relevant tissue intermediates have not
  been established. Current care is supportive; no disease-modifying treatment,
  disorder-specific practice guideline, or consensus tumor-screening protocol is
  available.
📚

References & Deep Research

References

5
PMID:31169992
DDX11-Related Cohesinopathy.
No top-level findings curated for this source.
PMID:20137776
Warsaw breakage syndrome, a cohesinopathy associated with mutations in the XPD helicase family member DDX11/ChlR1.
No top-level findings curated for this source.
PMID:30216658
Warsaw breakage syndrome: Further clinical and genetic delineation.
No top-level findings curated for this source.
PMID:30303954
Interaction of the Warsaw breakage syndrome DNA helicase DDX11 with the replication fork-protection factor Timeless promotes sister chromatid cohesion.
No top-level findings curated for this source.
PMID:26089203
The Warsaw breakage syndrome-related protein DDX11 is required for ribosomal RNA synthesis and embryonic development.
No top-level findings curated for this source.

Deep Research

1
Asta ▸
Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Warsaw breakage syndrome. Core disease mechanisms, molecular and cellular...
Asta Scientific Corpus Retrieval 20 citations 2026-04-15T19:44:52.549611

Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Warsaw breakage syndrome. Core disease mechanisms, molecular and cellular...

This report is retrieval-only and is generated directly from Asta results.

  • Papers retrieved: 20
  • Snippets retrieved: 20

Relevant Papers

[1] Role of the DDX11 DNA Helicase in Warsaw Breakage Syndrome Etiology

  • Authors: Diana Santos, M. Mahtab, A. Boavida, F. M. Pisani
  • Year: 2021
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/92bfe4899d538bf996264146a3bbf5e61bf512de
  • DOI: 10.3390/ijms22052308
  • PMID: 33669056
  • PMCID: 7956524
  • Citations: 8
  • Summary: What is known about the molecular and cellular functions of human DDX11 and its role in WABS etiopathogenesis is reviewed, even in light of recent findings on the role of cohesin and its regulator network in promoting chromatin loop formation and regulating chromatin spatial organization.
  • Evidence snippets:
  • Snippet 1 (score: 0.421) > Warsaw breakage syndrome (WABS) is a very rare autosomal recessive disease, due to biallelic mutations of the gene coding for the DDX11 DNA helicase [66,67]. The clinical spectrum of WABS is heterogeneous with some cardinal symptoms observed in all patients including: (1) severe pre-and post-natal growth retardation, (2) microcephaly, (3) sensorineural hearing loss, (4) cochlear anomalies, (5) facial dysmorphia and ( 6) sister chromatid cohesion defects. This latter clinical manifestation led to the notion that WABS is a cohesinopathy, even if not all the cohesinopathies are characterized by a precocious chromatid separation cellular phenotype [68]. Cohesinopathies are genetic diseases caused by mutations in genes involved in the sister chromatid cohesion process, including: Cornelia de Lange syndrome (CdLS), caused by mutations in genes encoding the cohesin structural components (SMC1A, SMC3 and RAD21) and regulators (NIPBL and HDAC8); Roberts syndrome (RBS), due to mutations of the cohesin acetyl-transferase gene (ESCO2) and chronic atrial and intestinal dysrhythmia (CAID) syndrome, linked to mutations of the SGOL1 gene encoding Shugoshin [68,69]. It should be pointed out that sister chromatid cohesion defects are observed in WABS and RBS patient cells, but not in those taken from CdLS or CAID probands. This can be due to the multiple functions played by the cohesin complex that are differentially affected in the various "cohesinopathies" [68][69][70]. The cohesion defects observed in metaphase chromosome spreads of WABS (and also RBS) immortalized fibroblasts mainly consist in a characteristic "railroad" configuration of the paired sisters with the centromere constriction that seems to be loosened (premature centromere division, PCD).

[2] Molecular and Cellular Functions of the Warsaw Breakage Syndrome DNA Helicase DDX11

  • Authors: F. M. Pisani, Ettore Napolitano, L. M. Napolitano, S. Onesti
  • Year: 2018
  • Venue: Genes
  • URL: https://www.semanticscholar.org/paper/04d885429b8d231e30c34cfd78ad49b67fea2c64
  • DOI: 10.3390/genes9110564
  • PMID: 30469382
  • PMCID: 6266566
  • Citations: 30
  • Influential citations: 1
  • Summary: The biochemical and structural features of DDX11 are illustrated and how it cooperates with multiple protein partners in the cell, acting at the interface of DNA replication/repair/recombination and sister chromatid cohesion to preserve genome stability.
  • Evidence snippets:
  • Snippet 1 (score: 0.406) > While sister chromatid cohesion defects were observed in all the patients described so far, two of these novel WABS patients do not display drug-induced elevated chromosomal breakage. Thus, while diagnostic clinical symptoms of WABS (microcephaly, growth retardation, cochlear anomalies and chromosomal cohesion defects) are observed in all cases reported in the literature, the chromosomal breakage phenotype is not universally present. In view of these findings, it was proposed to rename this disease "Warsaw syndrome", eliminating reference to the chromosomal breakage phenotype [84]. > The observed phenotypic differences among WABS patients may be due to the different effects of the DDX11 gene mutations and/or to different genetic background of the affected individuals. The ethiopathogenesis of WABS has not yet been deciphered as the cellular functions of DDX11 are not fully understood. However, the partial overlap of clinical manifestations (growth retardation, microcephaly, intellectual disability) with other cohesinopathies (CdLS and RBS) suggests that all these diseases share common developmental defects due to altered transcription profiles during embryonic development. This is consistent with the evidence that cohesin and its regulators play a role in stabilizing chromatin loops, through which developmental gene transcription programs are executed. In this context, it is interesting to point out that either DDX11 or Esco2 were reported to play an important function in chromosome architecture maintenance and their depletion in mammalian cells causes chromosome condensation defects in addition to sister chromatid cohesion anomalies, as described in Section 8. It was proposed that Esco2 could be responsible for recruiting chromatin modifiers (such as histone H3 methyltransferases and demethylases) affecting gene expression [92]. Moreover, DDX11 was believed to contribute to heterochromatin formation by targeting HP1α factor to proper sites in pericentric regions and at telomeres in DDX11-depleted HeLa and in DDX11 knockout mouse embryo-derived cells [67].

[3] Towards Mutation-Specific Precision Medicine in Atypical Clinical Phenotypes of Inherited Arrhythmia Syndromes

  • Authors: T. Nakajima, S. Tamura, M. Kurabayashi, Y. Kaneko
  • Year: 2021
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/3d299f57f344d42eff9d3565d1581dae7fb87a54
  • DOI: 10.3390/ijms22083930
  • PMID: 33920294
  • PMCID: 8069124
  • Citations: 6
  • Influential citations: 1
  • Summary: Since the epileptic phenotype appears to manifest prior to cardiac events in this mutation carrier, identifying KCND3 mutations in patients with epilepsy and providing optimal therapy will help prevent sudden unexpected death in epilepsy.
  • Evidence snippets:
  • Snippet 1 (score: 0.394) > Recent advances in molecular genetics have identified many causal genes for inherited arrhythmia syndromes (IASs) such as long QT syndrome (LQTS) [1], short QT syndrome (SQTS) [2], Brugada syndrome (BrS) [3,4] and early repolarization (ER) syndrome (ERS) [3,5]. Most causal genes for IASs encode cardiac ion channels or their related proteins. Genotype-phenotype studies and functional analyses of mutant genes, using heterologous expression systems and experimental animal models, have revealed the pathophysiology of IASs and enabled the establishment of causal gene-specific precision medicine [6][7][8]. Furthermore, analyses of patient-specific and/or genome-edited induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) have provided further insights into the pathophysiology of IASs and novel promising therapeutic strategies for IASs, although there are still some limitations of using iPSC-CMs, such as immature structure and function and mixed population of atrial, ventricular, and nodal cells, as a standard technology [9]. > The altered function of causal genes that encode cardiac ion channels is caused by multiple mechanisms, including trafficking defects, producing non-functional channels, altered channel gating properties, and a combination thereof. These altered functions of mutant channels underly the clinical phenotypes of IASs [10][11][12]. Particularly, unique electrophysiological properties of mutant channels have been shown to be associated with the atypical clinical phenotypes of IASs [10,13]. Furthermore, the elucidation of the mechanisms underlying the atypical clinical phenotypes of IASs has raised the possibility of mutation-specific precision medicine. > We herein review the current knowledge of genotype-phenotype relationships, underlying molecular and cellular mechanisms, and established pharmacological therapies of IASs, including LQTS, SQTS, and J wave syndrome (BrS and ERS).

[4] Clinical Phenotypes of Cardiovascular and Heart Failure Diseases Can Be Reversed? The Holistic Principle of Systems Biology in Multifaceted Heart Diseases

  • Authors: K. Lourida, G. Louridas
  • Year: 2022
  • Venue: Cardiogenetics
  • URL: https://www.semanticscholar.org/paper/3960806730c4c1115f527e22d6d0a76536570ec5
  • DOI: 10.3390/cardiogenetics12020015
  • Citations: 4
  • Influential citations: 1
  • Summary: Only by understanding the complexity of chronic heart diseases and explaining the interrelationship between different interconnected biological networks can the probability for clinical phenotypes reversal be increased.
  • Evidence snippets:
  • Snippet 1 (score: 0.383) > Treatment with ACEIs, ARBs, and β-blockers impedes deterioration of myocardial function as well as clinical deterioration caused by the deleterious impact of the compensatory systems [58,59]. Therefore, the therapy with ACEIs, ARBs, and β-blockers is the appropriate therapy to block LV remodeling and HF progression and reduce symptoms and/or mortality [55]. > In general, the HF syndrome demonstrates a modular construction with predictable behavior of functional clinical phenotypes having a strong impact on biological networks from epigenetic, cellular to regulatory systems [18]. The importance of individual genes for the pathogenesis and clinical progression of the HF syndrome is restricted to the hypertrophic and dilated cardiomyopathies. It seems that some HF patients have a complex multigenic inheritance, but the importance of individual genes is limited. In contrast, the significant role of epigenetics, proteomics, and metabolomics is increased; but, the complete genetic network system and the interactions between multiomics systems are still uncertain [60]. Multimodal systems that include genetic networks, multiomics, metabolic pathways, environmental factors, and sophisticated disease-related clinical networks are required to be integrated and provide a new holistic and realistic picture. > Significant breakthroughs have been made to understand many of the pathophysiological mechanisms of HFrEF but the natural pathophysiological history and clinical progression of HFpEF still remains inadequately defined [39]. The subclinical progression of pre-clinical diastolic dysfunction (PDD) of LV "to clinical phenotype of HFpEF and the further clinical progression to some more complex clinical models with multi-organ involvement . . . continue to be poorly understood" [40]. Prospective studies are expected to clarify the natural history and clinical progression of HFpEF and define the LV remodeling mechanisms involved. The pathophysiology of LV systolic dysfunction is different to the diastolic dysfunction, as systolic dysfunction is considered a disease of calcium handling and diastolic dysfunction is regarded as a disease of increased myofilament sensitivity to calcium [61][62][63].

[5] CHCHD2 up-regulation in Huntington disease mediates a compensatory protective response against oxidative stress

  • Authors: Xuanzhuo Liu, Fang Wang, Xinman Fan, Mingyi Chen, Xiaoxin Xu et al.
  • Year: 2024
  • Venue: Cell Death & Disease
  • URL: https://www.semanticscholar.org/paper/50ed416a063a1a7d3435fa600233ce0d7500986b
  • DOI: 10.1038/s41419-024-06523-x
  • PMID: 38341417
  • PMCID: 10858906
  • Citations: 18
  • Influential citations: 1
  • Summary: It is demonstrated that CHCHD2 up-regulation in HD serves as a compensatory protective response against oxidative stress, suggesting a potential anti-oxidative strategy for the treatment of HD.
  • Evidence snippets:
  • Snippet 1 (score: 0.378) > Huntington disease (HD) is a genetic neurodegenerative disease caused by the abnormal expansion of the CAG repeats encoding polyglutamine in the HTT gene resulting in the mutant huntingtin protein [1]. Currently, treatment options for HD are limited to symptom management, with no effective method to halt or delay disease progression. Research on HD pathogenesis holds great significance: the clear genetic basis of HD facilitates the establishment of animal and cellular models, providing a solid foundation for exploring underlying disease mechanisms and an opportunity to evaluate promising therapies in a well-defined patient population. Furthermore, HD shares clinical manifestations and molecular signaling pathway abnormalities with other neurodegenerative diseases like Alzheimer's disease (AD) and Parkinson's disease (PD), including specific subtypes of neuronal death and protein misfolding and deposition [2]. Therefore, investigating HD pathogenesis can offer important insights and ideas for the study and treatment of other neurodegenerative diseases. > The specific molecular mechanisms underlying HD pathogenesis remain incompletely understood, but previous studies have highlighted the involvement of oxidative stress in HD pathophysiology. For instance, increased oxidative stress has been observed in the peripheral blood of HD patients [3] and HD animal models [4]. Factors contributing to oxidative stress in HD include the aggregation of mutant huntingtin proteins, impaired antioxidant systems, elevated brain lipid content, high neuronal energy demands, mitochondrial electron transport chain damage, and mitochondrial dysfunction. HD cell mitochondria demonstrate significant alterations in morphology, structure, and Ca2 + homeostasis. These changes lead to reduced oxidative phosphorylation levels, inadequate ATP production, elevated levels of reactive oxygen species (ROS), and subsequent onset of oxidative stress. Excessive ROS levels are considered pathological markers of HD, inducing toxicity, contributing to further mitochondrial damage and protein misfolding, and ultimately resulting in neuronal death [5]. The nuclear factor NFE2-related factor 2-antioxidant response element (Nrf2-ARE) signaling pathway represents one of the most critical anti-oxidative stress pathways [6].

[6] A Journey through Huntington's Disease: Exploring Genetics, Neurobiology, and Therapeutic Advances

  • Authors: Sandeep Dey, Shreyas Katta, S. Suresh, Janhvi Mishra
  • Year: 2024
  • Venue: International Journal For Multidisciplinary Research
  • URL: https://www.semanticscholar.org/paper/735574648bec278cf15dc25fd5f1d735afaf6ae6
  • DOI: 10.36948/ijfmr.2024.v06i03.19194
  • Summary: The clinical features, ethics, and neurobiology of HD are discussed and the exciting approaches being employed today to advance understanding of underlying mechanisms in an effort to develop therapies that would delay the onset and slow progression of this disease are reviewed.
  • Evidence snippets:
  • Snippet 1 (score: 0.373) > Also, we present a modern view on the molecular biology of HD as a representative of the group of polyglutamine diseases, with an emphasis on conformational changes of mutant huntingtin, disturbances in its cellular processing, and proteolytic stress in degenerating neurons. > The main pathogenetic mechanisms of neurodegeneration in HD are discussed in detail, such as autophagy, impaired mitochondrial biogenesis, lysosomal dysfunction, organelle and protein transport, inflammation, oxidative stress, and transcription factor modulation. However, other unravelling mechanisms are still unknown. This practical and brief review summarises some of the currently known functions of the wild-type huntingtin protein and the recent findings related to the mechanisms involved in HD pathogenesis. Cellular mechanisms implicated in HD pathogenesis: The major mechanisms associated with HD pathogenesis are depicted here. The schematic shows a presynaptic neuron and a postsynaptic neuron flanked by two astrocytes. Huntingtin gene(HTT) itself is depicted as a "solenoid," based on the presumed folding due to its HEAT repeats. The mechanisms depicted are multimerization of mHtt-containing complexes, transcriptional modulation, ER-Golgi stress pathways, mitochondria and energy homeostasis, microtubular dynamics, endocytic and vesicular trafficking dynamics, autophagy, and synaptic signalling mechanisms. mHTT(mutant HTT protein). Traditionally, therapeutic approaches to HD have included compounds developed for psychiatric indications based on the affected neuronal circuitry: the frontal and motor corticostriatal circuits. None of these were initially developed for the treatment of HD. In this review we focus on the cellular and biological pathways affected by mutant HTT (mHTT) and the current status of associated drug discovery efforts. We also emphasise the need for further clinical research to validate existing hypotheses, which are mostly derived from animal studies and postmortem human tissues. It is generally accepted that most candidate therapeutics fail due to lack of efficacy in pivotal clinical studies.

[7] 18O-assisted dynamic metabolomics for individualized diagnostics and treatment of human diseases

  • Authors: E. Nemutlu, Song Zhang, N. Juranic, A. Terzic, S. Macura et al.
  • Year: 2012
  • Venue: Croatian Medical Journal
  • URL: https://www.semanticscholar.org/paper/880f053c7f060db4b990e447d0a22c4b69372ddb
  • DOI: 10.3325/cmj.2012.53.529
  • PMID: 23275318
  • PMCID: 3541579
  • Citations: 28
  • Summary: The potential use of dynamic phosphometabolomic platform for disease diagnostics currently under development at Mayo Clinic is described and discussed briefly.
  • Evidence snippets:
  • Snippet 1 (score: 0.368) > Living cells represent an integrated and interacting network of genes, transcripts, proteins, small signaling molecules, and metabolites that define cellular phenotype and function. Traditionally the focus of biomedical research was on individual genes, single protein targets, single metabolites, and metabolic or signaling pathways. This "molecular reductionist" paradigm was based on the assumption that identifying genetic variations and molecular components would lead to discovery of cures for human diseases. However, most of diseases are complex and multi-factorial and the disease phenotype is determined by the alterations of multiple genes, pathways, proteins and metabolites (at cellular, tissue, and organismal levels). Therefore, an integrated "omics" approach is more viable direction for uncovering alterations in metabolic networks, disease mechanisms, and mechanisms of drug effects. > Recent advent of large-scale metabolomics and fluxomic (metabolite dynamics and metabolic flux analysis) completed the "omics revolution" (Figure 1), where genomics, transcriptomics, proteomics, metabolomics, and fluxomics all together complement phenotype determination of living organism. Such integrated "omics" cascades provide a framework for advances in system and network biology, integrative physiology, and system medicine as well as system pharmacology and regenerative medicine. Noteworthy is the "reverse omic" approach or "metabolomicsinformed pharmacogenomics, " where discovery of specific metabolite changes have led to discovery of genetic alterations (2). Therefore, bringing new "omics" technologies to clinical practice will improve disease diagnostics and treatment by targeting drugs and procedures for each unique transcriptomic and metabolomic profiles.

[8] Molecular insights into the premature aging disease progeria

  • Authors: Sandra Vidak, R. Foisner
  • Year: 2016
  • Venue: Histochemistry and Cell Biology
  • URL: https://www.semanticscholar.org/paper/60fb3b46bb7e42d5d08cc3b7cbc783b118300c31
  • DOI: 10.1007/s00418-016-1411-1
  • PMID: 26847180
  • PMCID: 4796323
  • Citations: 105
  • Influential citations: 3
  • Summary: Changes in mechanosignaling, altered chromatin organization and impaired genome stability, and changes in signaling pathways, leading to impaired regulation of adult stem cells, defective extracellular matrix production and premature cell senescence are discussed.
  • Evidence snippets:
  • Snippet 1 (score: 0.367) > The number of molecular biological studies aiming at the identification of lamin-mediated molecular disease mechanisms involved in HGPS increased tremendously following the surprising discovery that LMNA is causally linked to the premature aging disease HGPS in 2003. Despite numerous cellular pathways that were identified to be affected by the expression of the mutant lamin A protein (Fig. 2), the mechanistic details behind these effects are still unclear in most cases. Knowledge based on what was already known on lamin biology before the protein was linked to HGPS and findings on novel roles of lamins in diverse pathways in recent years allowed the launch of translational studies and the efficient search for drug targets and therapeutic approaches within a short time period. The results of the first clinical trials taught us that some improvements of the disease phenotypes can be achieved by FTI treatment, but they also made clear that we need a much better understanding of the underlying disease mechanisms to be able to tackle specific aspects of the disease in a more focused approach. It will also be important to elucidate which of the numerous pathways found to be impaired in HGPS are most relevant for and causally involved in the pathologies, and which ones are just bystanders.

[9] Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?

  • Authors: C. Mulders-Manders, A. Simon
  • Year: 2015
  • Venue: Seminars in Immunopathology
  • URL: https://www.semanticscholar.org/paper/b0c6a9943fcdf22c8aece6bd26c62c9c7e9d31f7
  • DOI: 10.1007/s00281-015-0492-6
  • PMID: 25990874
  • PMCID: 4491100
  • Citations: 57
  • Influential citations: 2
  • Summary: New findings in this disorder that have been published in the last 2 years are discussed, including new insights into pathophysiology, treatment, and the clinical phenotype linked to the genetic defect.
  • Evidence snippets:
  • Snippet 1 (score: 0.363) > valonate aciduria, a severe disease characterized by neurologic involvement with psychomotor retardation, cerebellar ataxia, and facial dysmorphy besides the inflammatory symptoms, leading to early death. MKD forms a continuous spectrum of disease between these two clinical entities. Overlapping clinical syndromes are seen with increasing frequency. As there is no clear border between phenotypes, we will use the term mevalonate kinase deficiency, which encompasses both HIDS and mevalonate aciduria, to describe the disease in this paper. > In this review, we will discuss new findings in MKD that have been published between January 1, 2012 and December 31, 2014. > What is new on the pathophysiological mechanism of MKD? > In the past 30 years, MKD has been proven to be a typical monogenetic autoinflammatory disease with overproduction This article is a contribution to the Special Issue on The Inflammasome and Autoinflammatory Diseases -Guest Editors: Seth L. Masters, Tilmann Kallinich and Seza Ozen of the inflammatory cytokine interleukin-1 beta (IL-1β) as prominent pathophysiological mechanism [3][4][5][6][7]. The importance of this cytokine in MKD is backed up by the beneficial effects of IL-1β-targeting drugs such as anakinra in patients with this disease [8][9][10][11]. > Most studies on the pathophysiology of MKD are based on in vitro cellular models with murine [12][13][14] or human cells with drug-induced block of the mevalonate kinase pathway w i t h e i t h e r H M G -C o A r e d u c t a s e i n h i b i t o r s o r bisphosphonates (Fig. 1). In these models, LPS or other bacterial components are used to mimic the inflammatory stimulus needed for the production of IL-1β. Stimulation of monocytes with LPS leads to increased pro-IL-1β transcription via activation of transcription factor NF-kB [5]. The effects of bisphosphonates

[10] Transcriptional profiling of Hutchinson-Gilford progeria patients identifies primary target pathways of progerin

  • Authors: Sandra Vidak, Sohyoung Kim, Tom Misteli
  • Year: 2026
  • Venue: Nucleus
  • URL: https://www.semanticscholar.org/paper/4bd99b0875508364d8672b6da5a50d024d485a53
  • DOI: 10.1080/19491034.2025.2611484
  • PMID: 41489464
  • PMCID: 12773485
  • Summary: To probe the clinical relevance of previously implicated cellular pathways and to address the extent of gene expression heterogeneity between patients, transcriptomic analysis of a comprehensive set of HGPS patients finds misexpression of several cellular pathways, including multiple signaling pathways, the UPR and mesodermal cell fate specification.
  • Evidence snippets:
  • Snippet 1 (score: 0.362) > Oxidative stress represents another key pathogenic mechanism in HGPS, as impaired NRF2 activity or increased reactive oxygen species (ROS) levels are sufficient to recapitulate HGPSassociated phenotypes [17,32,60]. Collectively, these findings underscore the multifactorial nature of HGPS pathogenesis, implicating interconnected signaling cascades involved in inflammation, oxidative stress, proteostasis, and vascular remodeling. Reassuringly, our findings indicate that many of the major pathways that have been described to contribute to HGPS phenotypes in mouse and cellular disease models are also misregulated in progeria patients, and targeting these pathways may provide therapeutic avenues to mitigate disease severity and improve outcomes in HGPS. > Although individuals with HGPS typically exhibit a characteristic set of clinical features, such as craniofacial abnormalities, growth retardation, and cardiovascular complications, there is notable variability in the age of onset, severity, and progression of symptoms between patients [7,9]. At the cellular level, HGPS is associated with several hallmark abnormalities, including nuclear envelope defects, decreased expression of several nuclear proteins and epigenetic marks, mitochondrial dysfunction, and increased cellular senescence [1,11,30,31,61]. These cellular phenotypes also exhibit considerable variation between patients, possibly contributing to differences in clinical outcomes. Our results indicate that even though some degree of transcriptional heterogeneity between the individual patients exists, the majority of patients exhibit misregulation of a set of shared pathways, suggesting that these pathways are universal driver mechanisms in HGPS. Further work is needed to understand the molecular and genetic factors that underlie inter-individual variability in disease expression and progression. > A limitation of pathway analysis of HGPS patient samples is to distinguish the pathways which are directly targeted by the disease-causing progerin protein and the emergence of adaptive secondary response pathways during progression of the disease in patients during their lifetime. The same caveat applies to the use of cell-based models used in the study of HGPS disease mechanisms.

[11] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

  • Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
  • Year: 2025
  • Venue: Journal of Veterinary Internal Medicine
  • URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
  • DOI: 10.1111/jvim.70139
  • PMID: 40492724
  • PMCID: 12150350
  • Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
  • Evidence snippets:
  • Snippet 1 (score: 0.359) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[12] Replication stress as a driver of cellular senescence and aging

  • Authors: Lauren M. Herr, Ethan Schaffer, Kathleen F Fuchs, A. Datta, Robert Michael Brosh
  • Year: 2024
  • Venue: Communications Biology
  • URL: https://www.semanticscholar.org/paper/698be046efd479e99bba82c812613e880f855d44
  • DOI: 10.1038/s42003-024-06263-w
  • PMID: 38777831
  • PMCID: 11111458
  • Citations: 42
  • Summary: Recent advances demonstrating the role of replication stress as an ultimate driver of cellular senescence and aging are reviewed, highlighting connections to hallmarks of aging, hereditary accelerated aging disorders, and senotherapeutics.
  • Evidence snippets:
  • Snippet 1 (score: 0.358) > Warsaw Breakage Syndrome (WABS) is classified as a cohesinopathy disorder characterized by developmental abnormalities 58 .Although WABS does not fully resemble a classic premature aging disorder, the pre-and postnatal growth inhibition is accompanied by chromosomal instability, a hallmark of many more traditional hereditary accelerated aging diseases.The mutated DDX11 gene encodes a DNA helicase that interacts with proteins involved in replication fork protection and stability 59 (Table 2).Cells from WABS patients display reduced replication fork progression 59 .Moreover, cancer cell lines depleted of DDX11 by RNA interference or in which DDX11 was deleted by CRISPR were found to be hypersensitive to chemotherapy drugs that induce replication stress 60 .DDX11 is believed to resolve G-quadruplex (G4) DNA to enable smooth replication [61][62][63] .However, the precise relationship of G4 DNA metabolism to aging and the mechanistic function(s) of DDX11 in G4-induced replication stress have not yet been fully elucidated.

[13] Investigating the role of NPR1 in dilated cardiomyopathy and its potential as a therapeutic target for glucocorticoid therapy

  • Authors: Yaomeng Huang, Tongxin Li, Shichao Gao, Shuyu Li, Xiaoran Zhu et al.
  • Year: 2023
  • Venue: Frontiers in Pharmacology
  • URL: https://www.semanticscholar.org/paper/be229f6f2059faab4c97ec0a04bd055adab9dfe1
  • DOI: 10.3389/fphar.2023.1290253
  • PMID: 38026943
  • PMCID: 10662320
  • Citations: 3
  • Summary: Natriuretic peptide receptor 1 (NPR1) was identified as a core gene associated with DCM through bioinformatics analysis and led to substantial improvements in cardiac and renal function, accompanied by an upregulation of NPR1 expression.
  • Evidence snippets:
  • Snippet 1 (score: 0.357) > Multiple pathways and molecules are involved in this process; however, the detailed underlying mechanisms remain unclear. In recent years, with the development of high-throughput sequencing and gene chip technologies, the use of bioinformatics technology to explore the occurrence, development, and prognosis of diseases has become a hot topic for scholars worldwide (Hwang et al., 2018;Nayor et al., 2019;Rinschen et al., 2019;Sturm et al., 2019;Montaner et al., 2020). > The present study aimed to use bioinformatics technology to screen for DCM-related genes and investigate their mechanisms, with the purpose of revealing the pathogenesis of DCM and seeking treatment methods. The GSE3586 dataset, containing expression profiles related to DCM, was selected from the Gene Expression Omnibus (GEO) database. This study aimed to predict the core genes that may play crucial roles in disease progression at the molecular level through the enrichment of relevant molecular pathways associated with DCM. Furthermore, the phenotype of the core genes was validated to further support the results of the bioinformatics analysis through basic and clinical experiments. Additionally, the role of glucocorticoids in DCM treatment is discussed in this article with the purpose of providing a theoretical and experimental basis for exploring the pathogenesis of DCM and elucidating therapeutic methods. This study also provides a theoretical reference for the interpretation, early diagnosis, and treatment of DCM.

[14] Rare Monogenic Diseases: Molecular Pathophysiology and Novel Therapies

  • Authors: I. Condò
  • Year: 2022
  • Venue: International Journal of Molecular Sciences
  • URL: https://www.semanticscholar.org/paper/6aece75e6947f102b657851b74e8b96df5e654c1
  • DOI: 10.3390/ijms23126525
  • PMID: 35742964
  • PMCID: 9223693
  • Citations: 16
  • Influential citations: 2
  • Summary: A rare disease is defined by its low prevalence in the general population and its presence in a very small number of people.
  • Evidence snippets:
  • Snippet 1 (score: 0.355) > The selective expression or the particular role of specific genes in a single tissue explains the appearance of organ-specific inherited diseases. This is the case of genetic disorders of the kidney, which include dominant and recessive forms of cystic diseases, and renal tubulopathies. Mutations in polycystin-1 (PKD1) or -2 (PKD2) genes lead to autosomaldominant polycystic kidney disease (ADPKD), whose gender-dependent phenotype was analyzed in the study by Talbi et al. [9]. These results, obtained in mice lacking PKD1 expression, show the involvement of intracellular Ca2+ levels in the more severe phenotype affecting male ADPKD animals. Altogether, identification of the molecular mechanisms underlying enhanced Ca2+ signaling and proliferation in cells from male kidneys may contribute to develop novel therapeutics for ADPKD [9]. The autosomal-recessive form of polycystic kidney disease (ARPKD) mostly arises from defects in the gene named polycystic kidney and hepatic disease 1 (PKHD1), whereas a minority of cases is linked to a second causative gene DZIP1L. To examine the still unclear molecular pathophysiology of ARPKD, Cordido et al. recapitulate known molecular disease mechanisms and possible therapeutic approaches, from cellular and animal models to clinical trials [10]. The knowledge of ARPKD pathogenic pathways, involving the epidermal growth factor receptor (EGFR) axis, the production of adenylyl cyclase adenosine 3 ,5 -cyclic monophosphate (cAMP) and the activation of several protein kinases, begins to stimulate possible pharmacological interventions [10]. Inherited loss of function in various electrolyte transport proteins located along the nephron leads to two types of kidney tubulopathy with overlapping clinical symptoms: Gitelman and Bartter syndromes. The review by Nuñez-Gonzalez et al. aims to explain the different molecular basis of these difficult to diagnose monogenic syndromes. Moreover, the authors provide an overview of current therapeutic approaches and highlight the presence of common and specific options for Gitelman and Bartter patients [11].

[15] Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response

  • Authors: P. Mesdom, R. Colle, É. Lebigot, S. Trabado, Eric Deflesselle et al.
  • Year: 2020
  • Venue: Current Neuropharmacology
  • URL: https://www.semanticscholar.org/paper/79368e365458486de96794333613c12a6063bf54
  • DOI: 10.2174/1570159X17666191021141057
  • PMID: 31631822
  • PMCID: 7327943
  • Citations: 12
  • Summary: This review highlights the great and still underused potential of HDF, which stands out as a very promising tool in the understanding of MDD and AD mechanisms of action.
  • Evidence snippets:
  • Snippet 1 (score: 0.354) > Background: Human dermal fibroblasts (HDF) can be used as a cellular model relatively easily and without genetic engineering. Therefore, HDF represent an interesting tool to study several human diseases including psychiatric disorders. Despite major depressive disorder (MDD) being the second cause of disability in the world, the efficacy of antidepressant drug (AD) treatment is not sufficient and the underlying mechanisms of MDD and the mechanisms of action of AD are poorly understood. Objective The aim of this review is to highlight the potential of HDF in the study of cellular mechanisms involved in MDD pathophysiology and in the action of AD response. Methods The first part is a systematic review following PRISMA guidelines on the use of HDF in MDD research. The second part reports the mechanisms and molecules both present in HDF and relevant regarding MDD pathophysiology and AD mechanisms of action. Results HDFs from MDD patients have been investigated in a relatively small number of works and most of them focused on the adrenergic pathway and metabolism-related gene expression as compared to HDF from healthy controls. The second part listed an important number of papers demonstrating the presence of many molecular processes in HDF, involved in MDD and AD mechanisms of action. Conclusion The imbalance in the number of papers between the two parts highlights the great and still underused potential of HDF, which stands out as a very promising tool in our understanding of MDD and AD mechanisms of action

[16] New therapeutic targets in rare genetic skeletal diseases

  • Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
  • Year: 2015
  • Venue: Expert Opinion on Orphan Drugs
  • URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
  • DOI: 10.1517/21678707.2015.1083853
  • PMID: 26635999
  • PMCID: 4643203
  • Citations: 37
  • Influential citations: 1
  • Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
  • Evidence snippets:
  • Snippet 1 (score: 0.353) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[17] The Classification of Autosomal Recessive Cerebellar Ataxias: a Consensus Statement from the Society for Research on the Cerebellum and Ataxias Task Force

  • Authors: M. Beaudin, A. Matilla-Dueñas, B. Soong, J. Pedroso, O. Barsottini et al.
  • Year: 2019
  • Venue: Cerebellum (London, England)
  • URL: https://www.semanticscholar.org/paper/8be333265c4faffaeb605213aa48cb23b33981c1
  • DOI: 10.1007/s12311-019-01052-2
  • PMID: 31267374
  • PMCID: 6867988
  • Citations: 49
  • Summary: A consensus is built on the classification of autosomal recessive ataxias in order to develop a general approach to a patient presenting with ataxia, organize disorders according to clinical presentation, and define this field of research by identifying common pathogenic molecular mechanisms in these disorders.
  • Evidence snippets:
  • Snippet 1 (score: 0.352) > The importance of a proper recessive ataxia classification goes beyond the clinical diagnosis perspective. Autosomal recessive ataxias can be regrouped according to the deficient cellular and metabolic pathways involved, which provide a better understanding of cerebellar physiology and of its selective vulnerability to certain metabolic defects. This is also essential from a therapeutic perspective, as disorders that belong to the same metabolic pathway may to the same treatment options, indicating potential for drug repurposing. Figure 3 presents a pathophysiological classification of autosomal recessive ataxias. Certain genes are presented more than once since some proteins are involved in several metabolic pathways or may interfere with other cellular processes as they accumulate in neurons or glial cells. Table 3 presents a more detailed listing of the pathogenic pathways involved along with relevant references. Certain pathways are predominantly involved, notably mitochondrial dysfunction, which may result from abnormal mitochondrial DNA maintenance with progressive mutagenesis, defective mitochondrial protein synthesis and quality control, increased levels of reactive oxygen species and oxidative stress, deficient coenzyme Q10 metabolism, altered mitochondrial dynamics, defective mitochondrial chain assembly, or abnormal mitochondrial RNA maturation and processing (Table 3). Interestingly, many of the disorders caused by mitochondrial dysfunction also present with a mitochondrial clinical syndrome as shown in Fig. 1. Disorders of DNA repair mechanisms are also common, with double-strand break repair pathway or single-strand break repair complexes predominantly involved. Pathogenic mutations in these genes are also associated with a susceptibility to ionizing radiations and predisposition for cancers, but the neurological syndrome is characterized by cerebellar involvement and extrapyramidal movement disorders. It remains debated whether defective DNA repair is the main pathogenic mechanism causing the neurological phenotype [230], but the fact that several interacting genes in this pathway are involved in degenerative cerebellar ataxias suggests that the cerebellum has a peculiar susceptibility to DNA damage for which the underlying mechanism is not understood. Finally, altered synaptic morphology or synaptic dysfunction of Purkinje cells (PC) is frequently involved in recessive ataxias and is associated with aberrant Fig. 1 Clinical classification of autosomal recessive ataxias.

[18] The hyperornithinemia–hyperammonemia-homocitrullinuria syndrome

  • Authors: D. Martinelli, D. Diodato, Emanuela Ponzi, M. Monné, S. Boenzi et al.
  • Year: 2015
  • Venue: Orphanet Journal of Rare Diseases
  • URL: https://www.semanticscholar.org/paper/ed033868ee677da141e5c926bc7c93cac242ea06
  • DOI: 10.1186/s13023-015-0242-9
  • PMID: 25874378
  • PMCID: 4358699
  • Citations: 93
  • Influential citations: 5
  • Summary: The clinical phenotype of HHH syndrome is extremely variable and its severity does not correlate with the genotype or with recorded ammonium/ornithine plasma levels, suggesting the need for a better understanding of the still unsolved pathophysiology of the disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.349) > Although the disease responds well to treatment with low risk of relapse of hyperammonemia [38], slowly progressive pyramidal signs characterize the chronic course, as also seen in argininemia [89]. However, the mechanism(s) of pyramidal dysfunction in HHH syndrome still remains to be elucidated. Creatine deficiency may contribute to the pathogenetic mechanism of the syndrome, as creatine is relevant for mitochondrial energy metabolism, regulation of glycolysis, proteins synthesis, membrane stabilization and neuromodulation [77,78,85]. This could be in line with the finding of abnormally shaped mitochondria at electron microscopy studies in skin fibroblasts, hepatocytes and muscle biopsy from HHH syndrome patients [11,23,82]. Furthermore, a mitochondrial dysfunction has been recently related to the effects of ornithine and homocitrulline in causing oxidative stress and disturbed mitochondrial homeostasis [79,80]. > A further mechanism that can be involved in the pathophysiology of HHH syndrome is related to polyamines metabolism. Shimizu and colleagues reported increased total and fractional (putrescine, cadaverine, spermine, spermidine) polyamines in one HHH syndrome patient [30]. Indeed, the clinical similarities between HHH syndrome and argininemia, which has been associated to an abnormal polyamine metabolism [91,92], may suggest a common pathogenetic mechanism causing pyramidal dysfunction. > Overall, the pathogenesis of HHH syndrome is complex and not completely understood. It is likely that different mechanisms, including the impact of low mitochondrial ornithine on UC flux, the presence of hyperammonemic crises and the disturbance of other pathways in major organs play a role in determining the heterogeneous clinical presentation of ORC1 deficiency. > In addition, as molecular studies failed to disclose a correlation between type of mutations or ornithine transport capacity and disease severity, an effect of genetic modifiers, such as ORC genes redundancy, seems to be likely, but further studies are certainly needed to clarify this point.

[19] Molecular Pathogenesis in Myeloid Neoplasms with Germline Predisposition

  • Authors: Juehua Gao, Yihua Chen, M. Sukhanova
  • Year: 2021
  • Venue: Life
  • URL: https://www.semanticscholar.org/paper/e92b2ee66272a4073ff4b6dfa5993cb9e23c577c
  • DOI: 10.3390/life12010046
  • PMID: 35054439
  • PMCID: 8779845
  • Citations: 5
  • Summary: This review uses examples of these disorders to illustrate the key molecular pathways of myeloid neoplasms and models and tools that can further understand the biology and molecular mechanisms of this disease.
  • Evidence snippets:
  • Snippet 1 (score: 0.349) > The risk of developing a myeloid neoplasm is increased in patients with bone marrow failure syndromes, including Fanconi anemia (FA), severe congenital neutropenia, dyskeratosis congenita, Shwachman-Diamond syndrome, and Diamond-Blackfan anemia. Although the molecular mechanisms of these disorders have not entirely been elucidated, the concept of dysfunctional DNA repair being responsible for the main pathophysiology of FA is well accepted. As a result, cells from patients with FA display hypersensitivity to DNA cross-linking agents, such as mitomycin C (MMC) and diepoxybutane (DEB), revealing an increased rate of chromosome breakage upon exposure to one of these two agents. The chromosome breakage test has been developed as a clinical diagnostic test for patients with clinical suspicion of having FA. If positive, next-generation sequencing testing with a panel of FA genes is recommended to detect mutations and affected genes associated with FA for further family studies in order to identify mutation carriers. Many FA genes have been identified and grouped into broad categories: the FA core complex, ID2 complex proteins (FANCD2 (FA Complementation Group D2), FANCI (FA Complementation Group I)), and a group of proteins in the downstream functional units. Proteins in the FA core complex work together to activate the ID2 complex and downstream proteins to bring in DNA repair proteins. Mutations in any of the genes involved in the FA pathway impair DNA repair, especially the homologous recombination repair of double-strand DNA damage. Hematopoietic elements are particularly sensitive to this defect. According to the International Fanconi Anemia Registry Study, the risk of developing either MDS or AML before the age of 20 is 27%, and it rapidly increases to 52% by the age of 40 [42]. The mechanism of leukemogenesis in FA is thought to be due to emerged malignant clones harboring mutations that allow them to evade cell cycle regulation and apoptosis, leading to MDS and AML [43].

[20] Therapies for Mitochondrial Disease: Past, Present, and Future

  • Authors: Megan Ball, Nicole J. Van Bergen, A. Compton, David R Thorburn, S. Rahman et al.
  • Year: 2025
  • Venue: Journal of Inherited Metabolic Disease
  • URL: https://www.semanticscholar.org/paper/196ee50a950f29bc4134cfb8fe6bdfa9a3a1468b
  • DOI: 10.1002/jimd.70065
  • PMID: 40714961
  • PMCID: 12301291
  • Citations: 3
  • Summary: The latest developments in the pursuit to identify effective treatments for mitochondrial disease are examined and the barriers impeding their success in translation to clinical practice are discussed.
  • Evidence snippets:
  • Snippet 1 (score: 0.348) > Mitochondrial disease is a diverse group of clinically and genetically complex disorders caused by pathogenic variants in nuclear or mitochondrial DNA‐encoded genes that disrupt mitochondrial energy production or other important mitochondrial pathways. Mitochondrial disease can present with a wide spectrum of clinical features and can often be difficult to recognize. These conditions can be devastating; however, for the majority, there is no targeted treatment. In the last 60 years, mitochondrial medicine has experienced significant evolution, moving from the pre‐molecular era to the Age of Genomics in which considerable gene discovery and advancement in our understanding of the pathophysiology of mitochondrial disease have been made. In the last decade, in response to the urgent need for effective treatments, a wide range of emerging therapies have been developed, driven by innovative approaches addressing both the genetic and cellular mechanisms underpinning the diseases. Emerging therapies include dietary intervention, small molecule therapies aimed to restore mitochondrial function, stem cell or liver transplantation, and gene or RNA‐based therapies. However, despite these advances, translation to clinical practice is complicated by the sheer genetic and clinical complexity of mitochondrial disease, difficulty in efficient and precise delivery of therapies to affected tissues, rarity of individual genetic conditions, lack of reliable biomarkers and clinically relevant outcome measures, and the dearth of natural history data. This review examines the latest developments in the pursuit to identify effective treatments for mitochondrial disease and discusses the barriers impeding their success in translation to clinical practice. While treatment for mitochondrial disease may be on the horizon, many challenges must be addressed before it can become a reality.

Notes

  • This provider combines search_papers_by_relevance with snippet_search.
  • No synthesis or second-stage model call is performed.